6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one derivatives and related compounds as PTPN11 (SHP2) inhibitors for cancer therapy

JP7579402B2Active Publication Date: 2024-11-07NABEEL PHARMA INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2023132960
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-11-30
Filing Date
2023-08-17
Publication Date
2024-11-07
Estimated Expiration
2039-08-09

AI Technical Summary

Benefits of technology

が本明細書に記載される症状又は障害の治療に生じることになる。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579402000123
    Figure 0007579402000123
  • Figure 0007579402000124
    Figure 0007579402000124
  • Figure 0007579402000001
    Figure 0007579402000001
Patent Text Reader

Abstract

To provide inhibitors of PTPN11 (SHP2) for the treatment or prevention of cancer and other PTP-mediated diseases.SOLUTION: The present invention relates to 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one derivatives and related compounds which are useful as inhibitors of PTPN11 (SHP2) for the treatment or prevention of cancer and other PTP-mediated diseases. A preferred compound is, e.g., 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(Ra)-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-2,5-dimethylpyrimidin-4(3H)-one (example 18b) with a IC50 of 3 nM in a PTPN11-E76K mutant enzyme inhibition assay.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 717,588, filed August 10, 2018, and U.S. Provisional Patent Application No. 62 / 773,921, filed November 30, 2018, each of which is incorporated by reference in its entirety for all purposes.

[0002] Statement of Rights to Inventions Made Under Federally Sponsored Research and Development Not applicable

[0003] REFERENCE TO A "SEQUENCE LISTING," TABLE, OR COMPUTER PROGRAM LISTING CONTAINED ON A COMPACT DISC Not applicable [Background technology]

[0004] This specification discloses novel compounds and pyrimidinone-based compounds for the treatment of diseases, and the use of these compounds as pharmaceuticals. Also provided are methods for inhibiting PTPN11 (SHP2) activity in a human or animal subject for the treatment of diseases such as cancer, including leukemia and melanoma, as well as breast cancer, lung cancer, and colon cancer.

[0005] Tyrosine phosphorylation regulates cellular processes from human cell differentiation to cell proliferation and apoptosis, among others. Tyrosine phosphorylation is regulated by protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs). It is believed that cancer results from dysfunction of this regulation, which is governed by the activity of PTKs and PTPs, and PTK inhibitors have been developed as promising cancer treatments. Recent studies have also revealed the role of PTPs in cellular regulation (AJ Barr et al., Cell, 2009, vol. 136, pp. 352-363; JN Andersen et al., Mol. Cell. Biol., 2001, vol. 21, pp. 7117-7136).

[0006] Non-receptor protein tyrosine phosphatase 11 (PTPN11, also known as Src homology 2 phosphatase (SHP2)) is a non-receptor protein tyrosine phosphatase encoded by the PTPN11 gene. This PTP contains two tandem Src homology 2 (SH2) domains that function as phosphotyrosine-binding domains, a catalytic domain, and a C-terminal tail. In the basal state, the protein typically exists in an inactive autoinhibited conformation in which the active site is blocked by the N-terminal SH2 domain. Binding of phosphorylated proteins to these SH2 domains stimulates cytokine- and growth factor-mediated signaling, relieving this autoinhibition and making the active site available for PTPN11 to dephosphorylate its substrates (MG Mohl, BG Neel, Curr. Opin. Genetics Dev. 2007, 17:23-30; KS Grossmann, Adv. Cancer Res. 2010, 106:53-89; WQ Huang et al., Curr. Cancer Drug Targets 2014, 14:567-588. C. Gordon et al., Cancer Metastasis Rev. 2008, 27:179-192).

[0007] Germline and somatic mutations in PTPN11 leading to a gain of function of its catalytic activity have been reported in several diseases, including Noonan and Leopard syndromes, and multiple cancers, such as juvenile myelomonocytic leukemia, neuroblastoma, myelodysplastic syndrome, B-cell acute lymphoblastic leukemia / lymphoma, melanoma, acute myeloid leukemia, breast cancer, lung cancer, and colon cancer (MG Mohl, BG Neel, Curr. Opin. Genetics Dev. 2007, 17, 23-30). Recent studies have shown that a single PTPN11 mutation can cause Noonan syndrome, JMML-like myeloproliferative disorder, and acute leukemia in mice. These mutations disrupt the autoinhibition between the N-terminal SH2 domain and the catalytic site, allowing constitutive substrate access to the catalytic site of the enzyme (E. Darian et al., Proteins 2011, 79:1573-1588; ZH Yu et al., JBC 2013, 288:10472; W Qiu et al., BMC Struct. Biol. 2014, 14:10).

[0008] PTPN11 is widely expressed in most tissues and is involved in the regulation of various cell signaling events through multiple signaling pathways, including the Ras-MAPK pathway, the JAK-STAT pathway, or the PI3K-AKT pathway, which are important for diverse cellular functions, including cell proliferation, differentiation, cell cycle maintenance, EMT transition, cell division activation, metabolic control, transcriptional control, and cell migration (Tajan, M. et al., Eur. J. Medical Genetics, 2015, vol. 58, pp. 509-525; Prahallad, A. et al., Cell Reports, 2015, vol. 12, pp. 1978-1985).

[0009] Also, increasing evidence implicates PTPN11 / SHP2 in immune evasion during tumorigenesis, and thus immune responses in cancer patients may be stimulated by SHP2 inhibitors (Cancer Res. 2015 Feb 1;75(3):508-18; T Yokosuka T, J Exp Med. 2012;209(6):1201; S Amarnath, Sci Transl Med. 2011;3:111ra120; T Okazaki, PNAS 2001;98(24):13866-71).

[0010] Novel compounds and pharmaceutical compositions, some of which have been found to inhibit PTPN11 (SHP2), as well as methods for synthesizing these compounds and methods for using these compounds, including methods for treating PTP-mediated disorders in patients by administering these compounds. Summary of the Invention

[0011] In certain embodiments of the present invention, the compound or a salt or tautomer thereof has formula I [ka] where the subscripts a and b, Y1, Y2, and R1, R2, R3, R4, R5, R6, R7, R8, R9, R 10 , R 11 , and R 13 as presented herein.

[0012] In certain embodiments, the present invention provides a pharmaceutical composition comprising a compound of formula I in association with a pharma- ceutically acceptable carrier.

[0013] In certain embodiments, the present invention provides methods for inhibiting PTPN11 (SHP2) activity in a human or animal subject for the treatment of diseases such as cancer, including leukemia and melanoma, as well as breast cancer, lung cancer, and colon cancer. [Brief description of the drawings]

[0014] [Figure 1] FIG. 2 shows dose-dependent tumor growth inhibition by 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(Ra)-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one (Example 2b) in the KYSE520 xenograft model. [Diagram 2] FIG. 1 shows dose-dependent tumor growth inhibition by 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(Ra)-(2,3-dichlorophenyl)-2,5-dimethylpyrimidin-4(3H)-one (Example 10b) in the KYSE520 xenograft model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] I. Overview Certain compounds of formula I disclosed herein may have useful PTPN11 inhibitory activity and may be used to treat or prevent diseases or conditions in which PTPN11 plays an active role. Thus, in various aspects, certain embodiments also provide pharmaceutical compositions comprising one or more compounds disclosed herein together with a pharma- ceutically acceptable carrier, as well as methods of making and using said compounds and compositions. Certain embodiments provide methods for inhibiting PTPN11. Other embodiments provide methods for treating a patient in need of treatment for a PTPN11-mediated disorder, comprising administering to said patient a therapeutically effective amount of a compound or composition of the invention. Also provided is the use of certain compounds disclosed herein for use in the manufacture of a medicament for the treatment of a disease or condition ameliorated by the inhibition of PTPN11. In particular, said PTPN11-mediated disease is cancer.

[0016] II. Definition As used herein, the following terms have the meanings indicated.

[0017] When a range of values ​​is disclosed and the term "up to n1 to n2" or "between n1 and n2" is used, where n1 and n2 are numbers, the term is intended to include those values ​​themselves and the range between those values ​​unless otherwise specified. The range may be complete or continuous between and including those end values. For example, the range "up to 2 to 6 carbons" is intended to include 2, 3, 4, 5, and 6 carbons since carbon exists in whole number units. For example, compare the range "1 to 3 μM (micromolar)" to any number of significant figures (e.g., 1.255 μM, 2.1 μM, 2.9999 μM, etc.), which is intended to include 1 μM, 3 μM, and all concentrations therebetween.

[0018] As used herein, the term "about" is intended to modify the meaning of the numerical value it modifies, meaning that such value may vary within a margin of error. If no specific margin of error, such as the standard deviation for the average value found in the chart of data, is given, it should be understood that the term "about" means a range that encompasses the given value, as well as a range that would be included by rounding the number to the nearest whole number, taking into account significant figures.

[0019] The term "acyl," as used alone or in combination herein, refers to a carbonyl bound to an alkenyl, an alkyl, an aryl, a cycloalkyl, a heteroaryl, a heterocycle, or any other moiety where the atom bound to the carbonyl is carbon. An "acetyl" group refers to a -C(O)CH3 group. An "alkylcarbonyl" group or an "alkanoyl" group refers to an alkyl group bound to the parent molecular moiety through a carbonyl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl, and aroyl.

[0020] The term "alkenyl", as used alone or in combination herein, refers to a straight or branched chain hydrocarbon radical having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkenyl contains from 2 to 6 carbon atoms. The term "alkenylene" refers to a carbon-carbon double bond system bonded at two or more positions, such as ethenylene [(-CH=CH-), (-C::C-)]. Examples of suitable alkenyl radicals include ethenyl, propenyl, 2-methylpropenyl, 1,4-butadienyl, and the like. Unless otherwise specified, the term "alkenyl" may include "alkenylene" groups.

[0021] The term "alkynyl" refers to an alkynyl group having at least two carbon atoms and at least one triple bond and having the indicated number of carbon atoms (i.e., C 2~6 refers to a hydrocarbon of either a straight or branched chain (meaning 2 to 6 carbons). Alkynyl refers to any of the C2, C 2~3 , C 2~4 , C 2~5 , C 2~6 , C 2~7 , C 2~8 , C 2~9 , C 2~10 , C3, C 3~4 , C 3~5 , C 3~6 , C4, C 4~5 , C 4~6 , C5, C 5~6 Examples of alkynyl groups include, but are not limited to, acetylenyl, propynyl, 1-butynyl, 2-butynyl, butadinyl, 1-pentynyl, 2-pentynyl, isopentynyl, 1,3-pentadinyl, 1,4-pentadinyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 1,3-hexadinyl, 1,4-hexadinyl, 1,5-hexadinyl, 2,4-hexadinyl, or 1,3,5-hexatriyl.

[0022] The term "alkoxy" as used alone or in combination herein refers to an alkyl ether radical, where the term alkyl is as defined below. Examples of suitable alkyl ether radicals include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy, tert-butoxy, and the like.

[0023] The term "alkyl", as used alone or in combination herein, refers to a straight or branched chain alkyl radical containing from 1 to 20 carbon atoms. In certain embodiments, the alkyl contains from 1 to 10 carbon atoms. In other embodiments, the alkyl contains from 1 to 8 carbon atoms. The alkyl group is optionally substituted as defined herein. Examples of alkyl radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl, octyl, nonyl, and the like. The term "alkylene", as used alone or in combination herein, refers to a straight chain aliphatic group derived from a straight or branched chain saturated hydrocarbon bonded at two or more positions, such as methylene (-CH2-). Unless otherwise specified, the term "alkyl" may include an "alkylene" group.

[0024] The term "alkylamino," as used alone or in combination herein, refers to an alkyl group attached to the parent molecular moiety through an amino group. Suitable alkylamino groups can be mono- or di-alkylated forming groups, for example, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-ethylmethylamino, and the like.

[0025] The term "alkylthio" as used alone or in combination herein refers to an alkylthioether (RS-) radical, in which the term alkyl is as defined above and the sulfur may be oxidized with one or two atoms of oxygen. Examples of suitable alkylthioether radicals include methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio, sec-butylthio, tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like.

[0026] The terms "amido" and "carbamoyl", as used alone or in combination herein, refer to an amino group, as described below, attached to the parent molecular moiety through a carbonyl group, or vice versa. As used herein, an "amido" group includes "C-amido" and "N-amido" groups. As used alone or in combination herein, the term "C-amido" refers to a -C(O)N(RR') group, with R and R' as defined herein, or defined by a given "R" group specifically recited. In some embodiments, the "amido" group includes -C(O)NH2, C 1~4 Alkylamides and di(C 1~4 As used herein, "C alkyl" amides include 1~4 The term "alkylamide" refers to -C(O)NH(C 1~4 Alkyl), among which C 1~4 Alkyl is as defined herein. The term "N-amido" as used alone or in combination herein refers to a RC(O)N(R')- group with R and R' as defined herein or defined by a given "R" group specifically recited. The term "acylamino" as used alone or in combination herein includes an acyl group attached to the parent moiety through an amino group. An example of an "acylamino" group is acetylamino (CH3C(O)NH-).

[0027] As used herein alone or in combination, the term “amino” refers to —NRR′, in which R and R ’ is independently selected from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted, and R and R' may join to form a heterocycloalkyl, any of which may be optionally substituted.

[0028] The term "aryl" as used alone or in combination herein means a carbocyclic aromatic system containing one, two, or three rings, in which polycyclic ring systems have rings fused together. The term "aryl" encompasses aromatic groups such as phenyl, naphthyl, anthracenyl, and phenanthryl.

[0029] The terms "arylalkenyl" or "aralkenyl," as used herein alone or in combination, refer to an aryl group attached to the parent molecular moiety through an alkenyl group.

[0030] The terms "arylalkoxy" or "aralkoxy," as used alone or in combination herein, refer to an aryl group attached to the parent molecular moiety through an alkoxy group.

[0031] The terms "arylalkyl" or "aralkyl," as used alone or in combination herein, refer to an aryl group attached to the parent molecular moiety through an alkyl group.

[0032] The term aryloxy, as used alone or in combination herein, refers to an aryl group attached to the parent molecular moiety through an oxy.

[0033] The term "carbamate," as used alone or in combination herein, refers to an ester of carbamic acid (-NHCOO-), which may be attached to the parent molecular moiety through either the nitrogen or the acid terminus, and which is optionally substituted as defined herein.

[0034] The term "O-carbamyl," as used alone or in combination herein, refers to an --OC(O)NRR' group, with R and R' as defined herein.

[0035] The term "N-carbamyl," as used alone or in combination herein, refers to a ROC(O)NR'- group, with R and R' as defined herein.

[0036] As used herein, the term "carbonyl" when used alone includes formyl [-C(O)H] and when used in combination this term is a -C(O)- group.

[0037] As used herein, the term "carboxyl" or "carboxy" refers to -C(O)OH, or the corresponding "carboxylate" anion as present in a carboxylate salt. An "O-carboxy" group refers to a RC(O)O- group, where R is as defined herein. A "C-carboxy" group refers to a -C(O)OR group, where R is as defined herein.

[0038] The term "cyano," as used alone or in combination herein, refers to --CN.

[0039] The term "cycloalkyl" or "carbocycle", as used herein alone or in combination, refers to a saturated or partially saturated monocyclic, bicyclic, or tricyclic alkyl group, in which each cyclic moiety contains from 3 to 12 carbon atom ring members, and which may optionally be a benzo-fused ring system, substituted as defined herein. The term "cycloalkenyl" refers to a cycloalkyl group having one or two double bonds. In certain embodiments, the cycloalkyl (or cycloalkenyl) group contains from 5 to 7 carbon atoms. Examples of such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, tetrahydronaphthyl, indanyl, octahydronaphthyl, 2,3-dihydro-1H-indenyl, adamantyl, and the like. As used herein, "bicyclic" and "tricyclic" are intended to include fused ring systems such as decahydronaphthalene, octahydronaphthalene, and the like, as well as polycyclic (multicenter) ring systems that are both saturated or partially unsaturated. Isomers of the latter type are generally exemplified by bicyclo[1,1,1]pentane, camphor, adamantane, and bicyclo[3,2,1]octane.

[0040] The term "ester" as used alone or in combination herein refers to a carboxy group bridging two moieties which are attached at a carbon atom.

[0041] The term "ether" as used alone or in combination herein refers to an oxy group bridging two moieties which are attached at a carbon atom.

[0042] The terms "halo" or "halogen," as used alone or in combination herein, refer to fluorine, chlorine, bromine, or iodine.

[0043] The term "haloalkoxy," as used alone or in combination herein, refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.

[0044] The term "haloalkyl", as used herein alone or in combination, refers to an alkyl radical having the meaning as defined above, in which one or more hydrogens are replaced by halogen. Specifically included are monohaloalkyl radicals, dihaloalkyl radicals, and polyhaloalkyl radicals. As an example, monohaloalkyl radicals may have iodine, bromine, chlorine, or fluorine atoms in the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms, or a combination of different halo radicals. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, and dichloropropyl. "Haloalkylene" refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene (-CFH-), difluoromethylene (-CF2-), chloromethylene (-CHCl-), and the like.

[0045] The term "heteroalkyl" as used alone or in combination herein refers to a stable linear or branched chain, or combination thereof, that is fully saturated or has 1 to 3 degrees of unsaturation, composed of the indicated number of carbon atoms and 1 to 3 heteroatoms selected from N, O, and S, where the N and S atoms are optionally oxidized and the N heteroatom is optionally quaternized. The heteroatoms may be located at any position within the heteroalkyl group. Up to two heteroatoms may be consecutive, for example, -CH2-NH-OCH3.

[0046] The term "heteroaryl" as used alone or in combination herein refers to a 3-15 membered unsaturated monocyclic heterocycle or a fused monocyclic, bicyclic, or tricyclic ring system containing at least one atom selected from N, O, and S, where at least one of the fused rings is aromatic. In certain embodiments, the heteroaryl contains up to 1-4 heteroatoms as ring members. In other embodiments, the heteroaryl contains up to 1-2 heteroatoms as ring members. In certain embodiments, the heteroaryl contains up to 5-7 atoms. The term also encompasses fused polycyclic groups in which a heterocycle is fused to an aryl ring, where the heteroaryl ring is fused to another heteroaryl ring, where the heteroaryl ring is fused to a heterocycloalkyl ring, or where the heteroaryl ring is fused to a cycloalkyl ring. Examples of heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl, chromonyl, coumarinyl, benzopyranyl, tetrahydroquinolinyl, tetrazolopyridazinyl, tetrahydroisoquinolinyl, thienopyridinyl, furopyridinyl, pyrrolopyridinyl, and the like. Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl, and the like.

[0047] The term "heterocycloalkyl", and interchangeably the term "heterocycle", as used herein alone or in combination, refers to a saturated, partially unsaturated, or fully unsaturated (but non-aromatic), monocyclic, bicyclic, or tricyclic heterocyclic group, each of which contains at least one heteroatom as a ring member, each of which may be independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, the heterocycloalkyl contains up to 1-4 heteroatoms as ring members. In other embodiments, the heterocycloalkyl contains up to 1-2 heteroatoms as ring members. In certain embodiments, the heterocycloalkyl contains up to 3-8 ring members in each ring. In other embodiments, the heterocycloalkyl contains up to 3-7 ring members in each ring. In still other embodiments, the heterocycloalkyl contains up to 5-6 ring members in each ring. "Heterocycloalkyl" and "heterocycle" are intended to include sulfones, sulfoxides, N-oxides containing a tertiary nitrogen ring member, and carbocyclic and benzo-fused ring systems, and both terms also include systems in which a heterocycle is fused to an aryl group or to another heterocyclic group, as defined herein. Examples of heterocyclic groups include aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[1,3]oxazolo[4,5-b]pyridinyl, benzothiazolyl, dihydroindolyl, dihydropyridinyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like. Unless specifically prohibited, the heterocycle groups are optionally substituted.

[0048] The term "hydrazinyl," as used alone or in combination herein, refers to two amino groups linked by a single bond, ie, --NN--.

[0049] The term "hydroxy," as used alone or in combination herein, refers to --OH.

[0050] The term "hydroxyalkyl," as used herein alone or in combination, refers to a hydroxy group attached to the parent molecular moiety through an alkyl group.

[0051] The term "iminohydroxy" as used alone or in combination herein refers to =N(OH) and =NO-.

[0052] As used herein alone or in combination, the term “lower amino” refers to —NRR′, in which R and R ’ is independently selected from hydrogen and lower alkyl, either of which is optionally substituted.

[0053] The term "mercaptyl," as used alone or in combination herein, refers to an RS-group, with R as defined herein.

[0054] As used herein, the term "nitro" as used alone or in combination refers to --NO.sub.2.

[0055] The terms "oxy" or "oxa," as used alone or in combination herein, refer to --O--.

[0056] The term "oxo" as used alone or in combination herein refers to =O.

[0057] The term "perhaloalkoxy" refers to an alkoxy group in which all of the hydrogen atoms have been replaced by halogen atoms.

[0058] The term "perhaloalkyl," as used alone or in combination herein, refers to an alkyl group in which all of the hydrogen atoms have been replaced by halogen atoms.

[0059] As used herein, the term "ring" when referring to a chemical structure or position on a chemical structure, or equivalently, the term "cycle", refers to a group in which each atom is a member of a general ring structure. The ring may be saturated or unsaturated, including aromatic, unless otherwise specified, and may have between 3 and 9 members. When the ring is a heterocycle, it may be any of the following: B, N, O, S, C(O), S(O), aryl, ... m The ring may contain between 1 and 4 heteroatoms or heteroatom-containing groups selected from: Unless specifically prohibited, the ring is optionally substituted.

[0060] The terms "sulfonate," "sulfonic acid," and "sulfonic acid," as used alone or in combination herein, refer to the -SOH group and its anion when the sulfonic acid is used in salt formation.

[0061] The term "sulfanyl" as used alone or in combination herein refers to --S--.

[0062] As used herein, the term "sulfinyl," as used alone or in combination, refers to --S(O)--.

[0063] As used herein alone or in combination, the term "sulfonyl" refers to -S(O)2-.

[0064] The term "N-sulfonamido" refers to a RS(=O)2NR'- group, with R and R' as defined herein.

[0065] The term "S-sulfonamido" refers to a -S(=O)2NRR' group, with R and R' as defined herein.

[0066] The term "tautomer" as used herein alone or in combination refers to one of two or more isomers that interconvert quickly. Generally, this interconversion is fast enough that individual tautomers cannot be isolated in the absence of the other tautomers. The ratio of the amounts of tautomers may depend on the solvent composition, ionic strength, and pH, as well as other solution parameters. The ratio of the amounts of tautomers may vary with respect to a particular solution and may vary with respect to the microenvironment of a biomolecule binding site in the solution. Examples of tautomers well known in the art include keto / enol tautomers, enamine / imine tautomers, and lactam / lactim tautomers. Examples of tautomers well known in the art also include 2-hydroxypyridine / 2(1H)-pyridone tautomers, and 2-aminopyridine / 2(1H)-iminopyridone tautomers.

[0067] The terms "thia" and "thio" as used alone or in combination herein refer to the -S- group or ethers where the oxygen is replaced by a sulfur. The oxidized derivatives of the thio group, namely sulfinyl and sulfonyl, are included within the definition of thia and thio.

[0068] The term "thiol" as used alone or in combination herein refers to a --SH group.

[0069] As used herein, the term "thiocarbonyl" when used alone includes thioformyl-C(S)H and when used in combination the term is a -C(S)- group.

[0070] The term "N-thiocarbamyl" refers to a ROC(S)NR'- group, with R and R' as defined herein.

[0071] The term "O-thiocarbamyl" refers to an -OC(S)NRR' group, with R and R' as defined herein.

[0072] The term "thiocyanato" refers to the group -CNS.

[0073] Any definition herein may be used in conjunction with any other definition to describe a composite structural group. Conversely, the elements following any such definition are those that are attached to the parent moiety. For example, the composite group alkylamido would represent an alkyl group attached to the parent molecule via an amide group, and the term alkoxyalkyl would represent an alkoxy group attached to the parent molecule via an alkyl group.

[0074] When a group is defined to be "null", what is meant is that said group is absent.

[0075] The term "optionally substituted" means that the preceding group may be substituted or unsubstituted. When substituted, the substituents of an "optionally substituted" group may include, but are not limited to, one or more substituents independently selected from among the following groups or specifically named groups, either alone or in combination: lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, oxoalkyl ... , lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxy ester, lower carboxamide, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower haloalkylthio, lower perhaloalkylthio, arylthio, sulfonate, sulfonic acid, trisubstituted silyl, N3, SH, SCH3, C(O)CH3, CO2CH3, CO2H, pyridinyl, thiophene, furanyl, lower carbamate, and lower urea. Where structurally possible, two substituents may be linked to form a 5-, 6- or 7-membered fused carbocyclic ring or a heterocyclic ring composed of 0 to 3 heteroatoms, for example to form methylenedioxy or ethylenedioxy. An optionally substituted group may be unsubstituted (e.g., -CH2CH3), fully substituted (e.g., -CF2CF3), monosubstituted (e.g., -CH2CH2F), or substituted at a level between fully and monosubstituted (e.g., -CH2CF3). When a substituent is recited without any qualification as to substitution, both substituted and unsubstituted forms are encompassed. When the qualification "substituted" is attached to a substituent, the substituted form is specifically intended. Also, various sets of optional substituents for a particular moiety may be specified as needed, and in these cases, such optional substitutions will be specified, often following the words "optionally substituted with".

[0076] An R or R' term appearing alone and without a numbered designation, unless otherwise defined, refers to a moiety selected from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl, and heterocycloalkyl, any of which are optionally substituted. Such R and R' groups are to be understood as being optionally substituted as defined herein. Whether or not an R group has a numbered designation, R, R', and R groups with n=(1, 2, 3,...n) are all examples of R groups. n Each R group, each substituent, and each term, including, should be understood to be independent of each other with respect to the selection of groups. When any variable, substituent, or term (e.g., aryl, heterocycle, R, etc.) occurs more than once in a formula or general structure, its definition at each occurrence is independent of its definition at all other occurrences. Those skilled in the art will further understand that a particular group may be attached to a parent molecule or may occupy a given position from one end of an element chain. For example, an unsymmetrical group such as -C(O)N(R)- may be attached to the parent moiety at either the carbon or nitrogen position.

[0077] The term "bond" refers to a covalent bond between two atoms, or between two moieties when the atoms connected by the bond are considered to be part of a larger structure. The bond may be a single, double, or triple bond unless otherwise specified. A dotted line between two atoms in a drawing of a molecule represents the presence or absence of an additional bond at that position.

[0078] Asymmetric centers exist in the compounds disclosed herein. These centers are designated by the symbols "R" or "S" depending on the configuration of the substituents around this chiral carbon atom. It should be understood that the present invention encompasses all stereochemical isomers, including diastereomeric, enantiomeric, and epimeric forms, as well as d- and l-isomers, and mixtures thereof. Individual stereoisomers of the compounds can be prepared by synthesis from commercially available starting materials containing chiral centers, or by preparation and subsequent separation of a mixture of enantiomeric products, such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatography, direct separation of enantiomers on a chiral chromatography column, or any other suitable method known in the art. Starting compounds having a particular stereochemistry are commercially available or can be made and resolved by techniques known in the art. The compounds disclosed herein may also exist as geometric isomers. The present invention encompasses all cis, trans, syn, anti, entgegen (E) and zusammen (Z) isomers, as well as the appropriate mixtures thereof. Compounds may also exist as tautomers, and all tautomers are provided by the present invention. The compounds disclosed herein may also exist in unsolvated forms as well as solvated forms with pharma- ceutically acceptable solvents, such as water, ethanol, and the like. In general, solvated forms are considered equivalent to unsolvated forms.

[0079] The compounds disclosed herein have conformational isomers. [ka] When the aryl or heteroaryl is one of the groups [ka] and [ka] These forms are referred to as "S" depending on the conformation of the aryl or heteroaryl group with respect to the pyrimidinone moiety. a " or "R a " is designated by the symbol "S a " type and "R a Examples of this type can be seen in Examples 1-20.

[0080] As used herein, the term "disease" is intended to be generally synonymous with, and used interchangeably with, the terms "disorder," "syndrome," and "condition" (as in medical conditions), in that all reflect an abnormal condition of the human or animal body, or one of its body parts, that impairs normal functioning, is typically manifested by identifying signs and symptoms, and causes the human or animal to have a reduced survival or quality of life.

[0081] The term "combination therapy" refers to the administration of two or more therapeutic agents to treat a condition or disorder described in this disclosure in need of treatment. Such administration includes the co-administration of these therapeutic agents substantially simultaneously, for example in a single capsule with a fixed ratio of active ingredients, or in separate capsules for each active ingredient. Such administration also includes the use of the various therapeutic agents sequentially. In either case, this treatment regimen results in the beneficial effects of the drug combination in the treatment of the condition or disorder described herein.

[0082] A "PTPN11 inhibitor" is an inhibitor that has an IC50 of about 100 μM or less, more typically about 50 μM or less, with respect to PTPN11 activity as measured in the PTPN11 assay outlined herein. 50 "IC" is used herein to refer to a compound exhibiting 50" is the concentration of an inhibitor that reduces the activity of an enzyme (e.g., PTPN11) to half-maximal levels. Certain compounds disclosed herein have been found to exhibit inhibition against PTPN11. In certain embodiments, the compounds have an IC of about 50 μM or less with respect to PTPN11 as measured in the PTPN11 assay described herein. 50 and in other embodiments the compound exhibits an IC of about 10 μM or less with respect to PTPN11. 50 and in yet other embodiments, the compound exhibits an IC 50 and in yet other embodiments, the compound exhibits an IC 50 Shows.

[0083] The term "therapeutically effective" is intended to modify the amount of active ingredient used in the treatment of a disease or disorder or in the efficacy of a clinical endpoint.

[0084] The term "therapeutically acceptable" refers to a compound (or salt, prodrug, tautomer, zwitterion, etc.) that is suitable for use in contact with the tissues of a patient without undue toxic, inflammatory, or allergic response, meets a reasonable benefit / risk ratio, and is effective for the intended purpose.

[0085] As used herein, reference to "treatment" of a patient is intended to include prevention. Treatment may be of a prophylactic nature, i.e., treatment may include prevention of disease. Prevention of disease may include complete protection from disease, such as in the case of prevention of infection with a pathogen, or may include prevention of disease progression. For example, prevention of disease may not mean completely eliminating any effects associated with the disease at any level, but may instead mean preventing symptoms of the disease from reaching clinically significant or detectable levels. Prevention of disease may also mean preventing a disease from progressing to a later stage of the disease.

[0086] The term "patient" is generally synonymous with the term "subject" and includes all mammalian animals, including humans. Examples of patients include humans, farm animals such as cows, goats, sheep, pigs, and rabbits, and pet animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.

[0087] The term "prodrug" refers to a compound that is more active in vivo. Certain compounds disclosed herein may exist as prodrugs. Prodrugs of the compounds described herein are structurally modified versions of the compounds that undergo easy chemical changes under physiological conditions to become the compounds. Prodrugs may also be converted to the compounds by chemical or biochemical methods in an ex vivo environment. For example, a prodrug may be slowly converted to a compound when placed in a transdermal patch reservoir with an appropriate enzyme or chemical reagent. Prodrugs are often useful because in some situations they may be easier to administer than the compound or parent drug. For example, a prodrug may be bioavailable by oral administration, whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, including prodrugs that rely on hydrolytic cleavage or oxidative activation of themselves. A non-limiting example of a prodrug is a compound that is administered as an ester (the "prodrug"), but is subsequently metabolically hydrolyzed to the carboxylic acid, which is the active form. Other examples include peptidyl derivatives of compounds.

[0088] The compounds disclosed herein may exist as therapeutically acceptable salts. The present invention includes the compounds in salt form, including acid addition salts. Suitable salts include both salts formed with organic acids and salts formed with inorganic acids. Such acid addition salts will usually be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be useful in the preparation and purification of the compound in question. Base addition salts may also be formed and may be pharmaceutically acceptable.

[0089] As used herein, the term "therapeutically acceptable salt" refers to a salt or zwitterion of the compound disclosed herein that is soluble or dispersible in water or oil and therapeutically acceptable as defined herein. These salts can be prepared during the final isolation and purification of the compound, or can be prepared separately by reacting the free base form of the appropriate compound with a suitable acid. Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate (isethionate), lactate, maleate, and malonate. , DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphonate, picrate, pivalate, propionate, pyroglutamate, succinate, sulfonate, tartrate, L-tartrate, trichloroacetate, trifluoroacetate, phosphate, glutamate, bicarbonate, paratoluenesulfonate (p-tosylate), and undecanoate. Additionally, basic groups in the compounds disclosed herein can be quaternized with methyl chloride, methyl bromide, methyl iodide, ethyl chloride, ethyl bromide, ethyl iodide, propyl chloride, propyl bromide, propyl iodide, butyl chloride, butyl bromide, and butyl iodide, dimethyl sulfate, diethyl sulfate, dibutyl sulfate, and diamyl sulfate, decyl chloride, decyl bromide, decyl iodide, lauryl chloride, lauryl bromide, lauryl iodide, myristyl chloride, myristyl bromide, myristyl iodide, steryl chloride, steryl bromide, and steryl iodide, and benzyl bromide and phenethyl bromide.Examples of acids that can be used to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid, and organic acids such as oxalic acid, maleic acid, succinic acid, and citric acid. Salts can also be formed by coordination of the compounds with alkali metal ions or alkaline earth ions. Thus, the present invention contemplates sodium, potassium, magnesium, calcium, and the like salts of the compounds disclosed herein.

[0090] Base addition salts can be prepared by reacting the carboxyl group with a suitable base, such as the hydroxide, carbonate, or bicarbonate of a metal cation, or with ammonia or an organic primary, secondary, or tertiary amine during the final isolation and purification of the compound. Therapeutically acceptable salt cations include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as non-toxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N'-dibenzylethylenediamine. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.

[0091] Salts of a compound can be prepared by reacting the free base form of the appropriate compound with a suitable acid.

[0092] III. Compound In one embodiment, the present invention provides a compound of formula I [ka] A compound represented by the formula: the subscript a is 0 or 1; the subscript b is 0 or 1; Y1 is a direct bond or CR 17 R 18 and Y2 is C 1~4 Alkyl, Amino, C 1~4 AlkylC(O)O-, C 1~4 Alkylamino, and C 1~4 aminoalkyl; R1 is C 6~10 Aryl, C 3~8 Cycloalkyl, C 3~8 cycloalkenyl, and 5-10 membered heteroaryl groups having 1-4 heteroatoms or heteroatom groups independently selected from N, C(O), O, and S as ring members, wherein the aryl or heteroaryl of R1 is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkenyl, NR 15 C(O)R 14 , N.R. 15 C(O)OR 14 , N.R. 14 C(O)NR 15 R 16 , N.R. 15 S(O)R 14 , N.R. 15 S(O)2R 14 , C(O)NR 15 R 16 , S(O)NR 15 R 16 , S(O)NR 15 R 16 , C(O)R 14 , C(O)OR 14 , OR 14 , S.R. 14 , S(O)R 14 , and S(O)2R 14R is independently selected from the group consisting of 1 to 5 12 is substituted with a group, R2, R3, R 10 , and R 11 is hydrogen, C 1~4 Alkyl, and C 3~8 cycloalkyl; R4, R5, R8, and R9 are hydrogen, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, amino, hydroxy, C 3~8 Cycloalkyl, halo, and C 1~4 alkylamino; R6 is amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino; R7 is selected from the group consisting of hydrogen, amido, cyano, halo, and hydroxy, or R7 is C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 substituted with 1 to 5 groups independently selected from the group consisting of aminoalkyl; or R6 and R7 together with the carbon atom to which they are both attached are N, C(O), O, and S(O). m forming a 3- to 7-membered saturated or unsaturated ring having, as ring members, 0 to 3 heteroatoms or heteroatom groups independently selected from the subscript m is 0, 1, or 2; The saturated or unsaturated ring formed by R6 and R7 is unsubstituted or is selected from the group consisting of amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 substituted with 1 to 3 groups independently selected from the group consisting of aminoalkyl; R2, R3, R4, R5, R7, R8, R9, R 10 , and R 11 any two of the groups may form a 5- or 6-membered ring having 0 to 2 heteroatoms selected from N, O, and S as ring members; R2, R4, R6, R8, and R 10 any two groups may form a direct bond or a one or two carbon bridge; R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, -NH-NHR 19 , -NHR 19 , -OR 19 , -NHC(O)R 19 , -NHC(O)NHR 19 , -NHS(O)2NHR 19 , -NHS(O)2R 19 , -C(O)OR 19 , -C(O)NR 19 R 20 , -C(O)NH(CH2) q OH, -C(O)NH(CH2) q R 21 , -C(O)R 21 , -NH2, -OH, -S(O)2NR 19 R 20 , C 3~8 cycloalkyl, aryl, heterocyclyl having 1 to 5 heteroatoms selected from N, O, S, and P as ring members, and heteroaryl having 1 to 5 heteroatoms selected from N, O, S, and P as ring members, wherein the subscript q is an integer of 0 to 6, and the aryl, heteroaryl, heterocyclyl, and cycloalkyl are selected from C 1~4Alkyl, -OH, -NH2, -OR 21 , halo, cyano, and oxo; R 14 , R 15 , and R 16 is hydrogen, C 1~4 Alkyl, C 3~8 Cycloalkyl, C 6~10 aryl, and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of amido, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 substituted with one or more groups independently selected from the group consisting of: aminoalkyl; R 17 and R 18 is hydrogen, C 1~4 are each independently selected from the group consisting of alkyl, aryl, and CF3; R 19 and R 20 is hydrogen, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, and C 3~6 cycloalkyl; and Each R 21 is hydrogen, -OH, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, and C 3~6 independently selected from the group consisting of cycloalkyl, The compound, or a salt, ester, or prodrug thereof, is provided.

[0093] In some embodiments, the present invention provides a compound of formula I [ka] A compound represented by the formula: the subscript a is 0 or 1; the subscript b is 0 or 1; Y1 is a direct bond or CR 17 R 18 and Y2 is C 1~4 Alkyl, Amino, C 1~4 AlkylC(O)O-, C 1~4 Alkylamino, and C 1~4 aminoalkyl; R1 is C 6~10 Aryl, C 3~8 Cycloalkyl, C 3~8 cycloalkenyl, and 5-10 membered heteroaryl groups having 1-4 heteroatoms or heteroatom groups independently selected from N, C(O), O, and S as ring members, wherein the aryl or heteroaryl of R1 is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkenyl, NR 15 C(O)R 14 , N.R. 15 C(O)OR 14 , N.R. 14 C(O)NR 15 R 16 , N.R. 15 S(O)R 14 , N.R. 15 S(O)2R 14 , C(O)NR 15 R 16 , S(O)NR 15 R 16 , S(O)NR 15 R16 , C(O)R 14 , C(O)OR 14 , OR 14 , S.R. 14 , S(O)R 14 , and S(O)2R 14 R is independently selected from the group consisting of 1 to 5 12 is substituted with a group, R2, R3, R 10 , and R 11 is hydrogen, C 1~4 Alkyl, and C 3~8 cycloalkyl; R4, R5, R8, and R9 are hydrogen, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, amino, hydroxy, C 3~8 Cycloalkyl, halo, and C 1~4 alkylamino; R6 is amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino; R7 is selected from the group consisting of hydrogen, halo, and hydroxy, or R7 is amide, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 substituted with 1 to 5 groups independently selected from the group consisting of aminoalkyl; or R6 and R7 together with the carbon atom to which they are both attached are N, C(O), O, and S(O). m forming a 3- to 7-membered saturated or unsaturated ring having, as ring members, 0 to 3 heteroatoms or heteroatom groups independently selected from the subscript m is 0, 1, or 2; The saturated ring formed by R6 and R7 is unsubstituted or is selected from the group consisting of amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 substituted with 1 to 3 groups independently selected from the group consisting of aminoalkyl; R2, R3, R4, R5, R7, R8, R9, R 10 , and R 11 any two of the groups may form a 5- or 6-membered ring having 0 to 2 heteroatoms selected from N, O, and S as ring members; R2, R4, R6, R8, and R 10 any two groups may form a direct bond or a one or two carbon bridge; R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, -NH-NHR 19 , -NHR 19 , -OR 19 , -NHC(O)R 19 , -NHC(O)NHR 19 , -NHS(O)2NHR 19 , -NHS(O)2R 19 , -C(O)OR 19 , -C(O)NR 19 R 20 , -C(O)NH(CH2) q OH, -C(O)NH(CH2) q R 21 , -C(O)R 21 , -NH2, -OH, -S(O)2NR 19 R 20 , C 3~8cycloalkyl, aryl, heterocyclyl having 1 to 5 heteroatoms selected from N, O, S, and P as ring members, and heteroaryl having 1 to 5 heteroatoms selected from N, O, S, and P as ring members, wherein the subscript q is an integer of 0 to 6, and the aryl, heteroaryl, heterocyclyl, and cycloalkyl are selected from C 1~4 Alkyl, -OH, -NH2, -OR 21 , halo, cyano, and oxo; R 14 , R 15 , and R 16 is hydrogen, C 1~4 Alkyl, C 3~8 Cycloalkyl, C 6~10 aryl, and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of halo, hydroxy, cyano, and C 1~4 substituted with one or more groups independently selected from the group consisting of alkyl; R 17 and R 18 is hydrogen, C 1~4 are each independently selected from the group consisting of alkyl, aryl, and CF3; R 19 and R 20 is hydrogen, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, and C 3~6 cycloalkyl; and Each R 21 is hydrogen, -OH, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, and C 3~6 independently selected from the group consisting of cycloalkyl, The compound, or a salt, ester, or prodrug thereof, is provided.

[0094] In some embodiments of Formula I, Y is a direct bond. In some embodiments, Y is CR 17 R 18 In some embodiments, R 17 and R 18 is hydrogen, C 1~4 alkyl, and CF. In some embodiments, R 17 and R 18 are each independently hydrogen or C 1~4 In some embodiments, Y1 is -CH2.

[0095] In some embodiments of Formula I, Y2 is C 1~4 In some embodiments, Y2 is methyl.

[0096] In some embodiments, the compound has formula Ia [ka] wherein the subscripts a and b, Y1, R1, R2, R3, R 4、 R5, R6, R 7、 R8, R9, R 10 , R 11 , and R 13 is as defined and described herein.

[0097] In some embodiments, the compound has formula Ib [ka] wherein the subscripts a and b, Y2, R1, R2, R3, R 4、 R5, R6, R 7、 R8, R9, R 10 , R 11 , and R 13 is as defined and described herein.

[0098] In some embodiments, the compound has formula Ic [ka] wherein the subscripts a and b, R1, R2, R3, R 4、 R5, R6, R 7、 R8, R9, R 10 , R 11 , and R 13 is as defined and described herein.

[0099] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, the subscripts a and b are each 1.

[0100] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R 13 is hydrogen, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, C 3~8 cycloalkyl, 3- or 6-membered heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S as ring members, wherein the heterocyclyl and cycloalkyl are C 1~4 Alkyl, -OH, -NH2, -OR 21 In some embodiments, R is substituted with 0 to 3 groups independently selected from the group consisting of halo, cyano, and oxo. 13 is hydrogen, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, and C 3~8 In some embodiments, R is selected from the group consisting of cycloalkyl. 13 is hydrogen, halo, C 1~6 Alkyl, and C 1~6 In some embodiments, R is selected from the group consisting of haloalkyl. 13 is hydrogen, halo, C 1~4 Alkyl, and C 1~4In some embodiments, R is selected from the group consisting of haloalkyl. 13 is selected from the group consisting of -CHOH, CFOH, and -CHFOH. In some embodiments, R 13 is selected from the group consisting of hydrogen, Cl, Br, methyl, and CF. In some embodiments, R 13 is hydrogen. In some embodiments, R 13 is Cl. In some embodiments, R 13 is Br. In some embodiments, R 13 is methyl. In some embodiments, R 13 is CF3.

[0101] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is C 6~10 aryl and 5-9 membered heteroaryl groups having 1-4 heteroatoms independently selected from N, C(O), O, and S as ring members, and optionally halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkenyl, NR 15 C(O)R 14 , N.R. 15 C(O)OR 14 , N.R. 14 C(O)NR 15 R 16 , N.R. 15 S(O)R 14 , N.R. 15 S(O)2R 14 , C(O)NR 15 R 16 , S(O)NR 15 R 16 , S(O)NR 15 R 16 , C(O)R 14 , C(O)OR14、 OR 14 , S.R. 14 , S(O)R 14 , and S(O)2R 14 R is independently selected from the group consisting of 1 to 5 12 is substituted with a group.

[0102] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is C 6~10 aryl and 5-9 membered heteroaryl groups having 1-4 heteroatoms independently selected from N, C(O), O, and S as ring members, and optionally halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkenyl, NR 15 C(O)R 14 , N.R. 15 C(O)OR 14 , N.R. 14 C(O)NR 15 R 16 , N.R. 15 S(O)R 14 , N.R. 15 S(O)2R 14 , C(O)NR 15 R 16 , S(O)NR 15 R 16 , S(O)NR 15 R 16 , C(O)R 14 , C(O)OR 14、 OR 14 , S.R. 14 , S(O)R 14 , and S(O)2R 14 R is independently selected from the group consisting of 1 to 5 12 is substituted with an R 14 , R 15 , and R16 is hydrogen, C 1~4 Alkyl, C 3~8 Cycloalkyl, C 6~10 aryl, and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of amido, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 and substituted with one or more groups independently selected from the group consisting of aminoalkyl.

[0103] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is C 6~10 aryl and 5-9 membered heteroaryl groups having 1-4 heteroatoms independently selected from N, C(O), O, and S as ring members, and optionally halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkenyl, NR 15 C(O)R 14 , N.R. 15 C(O)OR 14 , N.R. 14 C(O)NR 15 R 16 , N.R. 15 S(O)R 14 , N.R. 15 S(O)2R 14 , C(O)NR 15 R 16 , S(O)NR 15 R 16 , S(O)NR 15 R 16 , C(O)R14 , C(O)OR 14 , OR 14 , S.R. 14 , S(O)R 14 , and S(O)2R 14 R is independently selected from the group consisting of 1 to 5 12 is substituted with an R 14 , R 15 , and R 16 is hydrogen, C 1~4 Alkyl, C 3~8 Cycloalkyl, C 6~10 aryl, and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of halo, hydroxy, cyano, and C 1~4 and substituted with one or more groups independently selected from the group consisting of alkyl.

[0104] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with a group.

[0105] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is hydrogen, C 1~4 Alkyl, C 3~8 Cycloalkyl, C 6~10 aryl, and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of amido, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 and substituted with one or more groups independently selected from the group consisting of aminoalkyl.

[0106] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is hydrogen, C 1~4 Alkyl, C 3~8 Cycloalkyl, C 6~10 aryl, and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of halo, hydroxy, cyano, and C 1~4 and substituted with one or more groups independently selected from the group consisting of alkyl.

[0107] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is C 6~10 aryl and 5-10 membered heteroaryl, each of which is optionally C 1~4 Alkylamide, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 and substituted with one or more groups independently selected from the group consisting of aminoalkyl.

[0108] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is C 6~10aryl and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of halo, hydroxy, cyano, and C 1~4 and substituted with one or more groups independently selected from the group consisting of alkyl.

[0109] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 and substituted with 1 or 2 groups independently selected from the group consisting of aminoalkyl.

[0110] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally selected from halo, hydroxy, cyano, and C 1~4 and substituted with one or more groups independently selected from the group consisting of alkyl.

[0111] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 and substituted with one or more groups independently selected from the group consisting of alkyl.

[0112] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide and C 1~4 and substituted with one or more groups independently selected from the group consisting of alkyl.

[0113] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms or groups of heteroatoms independently selected from N, C(O), O, and S as ring members, and optionally halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and C 1~4 one, two, or three R independently selected from the group consisting of: 12 is substituted with a group.

[0114] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R2, R3, R 10 , and R 11 are independently hydrogen or C 1~4 In certain embodiments, R, R, R 10 , and R 11 are hydrogen.

[0115] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R4, R5, R8, and R9 are hydrogen, C1~4 Alkyl, C 1~4 Alkoxy, amino, hydroxy, C 3~8 Cycloalkyl and C 1~4 In certain embodiments, R4, R5, R8, and R9 are independently selected from the group consisting of hydrogen or C 1~4 In certain embodiments, R4, R5, R8, and R9 are each hydrogen.

[0116] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms or groups of heteroatoms independently selected from N, C(O), O, and S as ring members, and optionally halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and C 1~4 one, two, or three R independently selected from the group consisting of: 12 R4, R5, R8, and R9 are each substituted with a hydrogen atom, 1~4 Alkyl, C 1~4 Alkoxy, amino, hydroxy, C 3~6 Cycloalkyl and C 1~4 alkylamino.

[0117] In some embodiments of any one of Formula I, Formula Ia, Formula Ib, and Formula Ic, R2, R3, R4, R5, R8, R9, R 10 , and R 11 are hydrogen.

[0118] In some embodiments, the compound has Formula II [ka] R1, R6, R7, and R 13 is as defined and described herein.

[0119] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R6 is amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino, R7 is selected from the group consisting of hydrogen, amido, cyano, halo, and hydroxy; or R7 is C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 In some embodiments, R6 is substituted with 1 to 3 substituents selected from the group consisting of amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino, R7 is selected from the group consisting of hydrogen, amido, halo, and hydroxy; or R7 is C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 and substituted with 1 or 2 substituents selected from the group consisting of alkoxy.

[0120] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R6 is amino, C 1~4 In some embodiments, R6 is selected from the group consisting of amino, aminoalkyl, and methylamino. 1~4In certain embodiments, R6 is amino, aminomethyl, or methylamino. In certain embodiments, R6 is amino or aminomethyl. In certain embodiments, R6 is amino. In certain embodiments, R6 is aminomethyl.

[0121] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R7 is hydroxy, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 In some embodiments, R7 is substituted with 1 or 2 groups selected from the group consisting of hydroxy, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 In some embodiments, R7 is selected from the group consisting of hydroxy, C 1~4 Alkyl or C 1~4 In certain embodiments, R7 is C 1~4 In certain embodiments, R7 is alkyl. In certain embodiments, R7 is methyl. In certain embodiments, R7 is ethyl.

[0122] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R6 is C 1~4 aminoalkyl, R7 is hydroxy, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4It is substituted with 1 to 3 groups independently selected from the group consisting of alkoxy.

[0123] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R6 is aminomethyl, R7 is hydroxy, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 It is selected from the group consisting of cycloalkyl, phenyl, and 5- or 6-membered heteroaryl.

[0124] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R6 is amino, R7 is hydroxy, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 It is substituted with 1 to 3 groups independently selected from the group consisting of alkoxy.

[0125] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R6 is amino, R7 is hydroxy, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 It is selected from the group consisting of cycloalkyl, phenyl, and 5- or 6-membered heteroaryl.

[0126] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R6 is amino and R7 is C 1~4 In some embodiments, R6 is amino and R7 is hydroxymethyl. In some embodiments, R6 is amino and R7 is C 1~4In certain embodiments, R6 is amino and R7 is methyl. In some embodiments, R6 is amino and R7 is ethyl. In some embodiments, R6 is aminomethyl and R7 is C 1~4 In certain embodiments, R6 is aminomethyl and R7 is methyl. In some embodiments, R6 is aminomethyl and R7 is ethyl.

[0127] In any of the above embodiments, the amide at R7 may specifically be -C(O)NH2.

[0128] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R and R, together with the carbon atom to which they are attached, are selected from N, C(O), O, and S(O). m and optionally an amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 The saturated or unsaturated ring is substituted with one or two groups independently selected from the group consisting of aminoalkyl.

[0129] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R and R are both taken together with the carbon atom to which they are attached to form a 4-6 membered saturated or unsaturated ring having 1-3 heteroatoms or groups of heteroatoms independently selected from N, C(O), and O as ring members, and optionally amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 The saturated or unsaturated ring is substituted with one or two groups independently selected from the group consisting of aminoalkyl.

[0130] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R and R, together with the carbon atom to which they are attached, are selected from N, C(O), O, and S(O). m and optionally an amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 The saturated ring is substituted with one or two groups independently selected from the group consisting of aminoalkyl.

[0131] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R and R are both taken together with the carbon atom to which they are attached to form a 4-6 membered saturated ring having 1-3 heteroatoms or groups of heteroatoms independently selected from N, C(O), and O as ring members, and optionally amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 The saturated ring is substituted with one or two groups independently selected from the group consisting of aminoalkyl.

[0132] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R and R are both taken together with the carbon atom to which they are attached to form a 4-6 membered saturated ring having 1-3 heteroatoms or groups of heteroatoms independently selected from N and O as ring members, and optionally amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 The saturated ring is substituted with one or two groups independently selected from the group consisting of aminoalkyl.

[0133] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R and R, together with the carbon atom to which they are attached, are optionally selected from amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 and forming a 3- to 7-membered cycloalkyl ring substituted with 1 or 2 groups independently selected from the group consisting of aminoalkyl.

[0134] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R and R, together with the carbon atom to which they are attached, are optionally selected from amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 and forming a 4- to 6-membered cycloalkyl ring substituted with 1 or 2 groups independently selected from the group consisting of aminoalkyl.

[0135] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 R6 is substituted by one or two groups independently selected from the group consisting of aminoalkyl, C 1~4 Aminoalkyl, and C 1~4 alkylamino, R7 is selected from the group consisting of hydrogen, halo, and hydroxy; or R7 is selected from the group consisting of amide, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 and substituted with 1 or 2 substituents selected from the group consisting of alkoxy.

[0136] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 R is substituted by one or two groups independently selected from the group consisting of aminoalkyl, R is amino or aminomethyl, R is hydroxy, C 1~4 Alkyl, and C 1~4 hydroxyalkyl.

[0137] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 and R6 and R7 together with the carbon atom to which they are attached represent N, C(O), O, and S(O). m and optionally an amino, halo, hydroxy, C 1~4 Alkyl, C 1~4Alkoxy, C 1~4 Alkylamino, and C 1~4 The saturated or unsaturated ring is substituted with one or two groups independently selected from the group consisting of aminoalkyl.

[0138] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 R6 and R7 are both substituted with one or two groups independently selected from the group consisting of aminoalkyl, R6 and R7 together with the carbon atom to which they are attached form a 4-6 membered saturated or unsaturated ring having 1-3 heteroatoms or heteroatom groups independently selected from N, C(O), and O as ring members, and optionally amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 The saturated or unsaturated ring is substituted with one or two groups independently selected from the group consisting of aminoalkyl.

[0139] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with an R 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 and R6 and R7, together with the carbon atom to which they are attached, are optionally substituted with one or two groups independently selected from the group consisting of amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 and forming a 3- to 7-membered cycloalkyl ring substituted with 1 or 2 groups independently selected from the group consisting of aminoalkyl.

[0140] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and C 1~4 one, two, or three R independently selected from the group consisting of: 12 R6 is substituted with amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino, R7 is selected from the group consisting of hydrogen, halo, and hydroxy; or R7 is selected from the group consisting of amide, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 and substituted with 1 or 2 substituents selected from the group consisting of alkoxy.

[0141] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and C 1~4 one, two, or three R independently selected from the group consisting of: 12 R is substituted with an amino or aminomethyl group, R is hydroxy, C 1~4 Alkyl, and C 1~4 hydroxyalkyl.

[0142] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and C 1~4 one, two, or three R independently selected from the group consisting of: 12 groups, and R and R together with the carbon atom to which they are attached are N, C(O), O, and S(O). m and optionally an amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 The saturated or unsaturated ring is substituted with one or two groups independently selected from the group consisting of aminoalkyl.

[0143] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and C 1~4 one, two, or three R independently selected from the group consisting of: 12R and R together with the carbon atom to which they are attached form a 4-6 membered saturated or unsaturated ring having 1-3 heteroatoms or heteroatom groups independently selected from N, C(O), and O as ring members, and optionally amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 The saturated or unsaturated ring is substituted with one or two groups independently selected from the group consisting of aminoalkyl.

[0144] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl or a 5-6 membered heteroaryl group having 1-4 heteroatoms as ring members independently selected from N, O, and S, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and C 1~4 one, two, or three R independently selected from the group consisting of: 12 groups, and R and R together with the carbon atom to which they are attached are optionally substituted with amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 and forming a 3- to 7-membered cycloalkyl ring substituted with 1 or 2 groups independently selected from the group consisting of aminoalkyl.

[0145] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, pyrazolyl, pyrazinyl, pyridazinyl, and 1,2,4-triazinyl, and optionally one, two, or three R 12 where each R 12is as defined and described herein. In some embodiments, R is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, and 1,2,4-triazinyl, and optionally one, two, or three R 12 where each R 12 is as defined and described herein. In some embodiments, R is phenyl or pyridyl, and optionally, one, two, or three R 12 where each R 12 is as defined and described herein.

[0146] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, and 1,2,4-triazinyl, and is optionally selected from the group consisting of halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 has been replaced with.

[0147] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, and 1,2,4-triazinyl, and is optionally selected from the group consisting of halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and C 1~4 one, two, or three R independently selected from the group consisting of: 12 has been replaced with.

[0148] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl or pyridyl, each of which is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 has been replaced with.

[0149] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl or pyridyl, each of which is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and C 1~4 one, two, or three R independently selected from the group consisting of: 12 has been replaced with.

[0150] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is phenyl, and optionally, one to three R 12 each of which is substituted with halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 In some embodiments, R1 is phenyl, and optionally, 1 to 3 R 12 each of which is substituted with halo, hydroxy, amino, methylamino, dimethylamino, cyano, C1~4 Alkyl, C 1~4 Haloalkyl and C 1~4 In some embodiments, R is phenyl, and optionally, 1 to 3 R 12 each of which is substituted with halo, hydroxy, C 1~4 Alkyl, and C 1~4 alkoxy.

[0151] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is pyridyl, and optionally, one to three R 12 each of which is substituted with halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 In some embodiments, R1 is pyridyl, and optionally, one to three R 12 each of which is substituted with halo, hydroxy, amino, methylamino, dimethylamino, cyano, C 1~4 Alkyl, C 1~4 Haloalkyl and C 1~4 In some embodiments, R is pyridyl, and optionally, one to three R 12 each of which is substituted with halo, hydroxy, C 1~4 Alkyl, and C 1~4 alkoxy.

[0152] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] and each R 12is as defined and described herein.

[0153] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] and Each R 12 are halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 R 14 is as defined and described herein.

[0154] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] and Each R 12 are halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and C 1~4 aminoalkyl.

[0155] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] and Each R 12 are halo, hydroxy, amino, methylamino, dimethylamino, cyano, C1~4 Alkyl, C 1~4 Haloalkyl and C 1~4 alkoxy.

[0156] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] and Each R 12 are halo, hydroxy, amino, methylamino, dimethylamino, cyano, C 1~4 Alkyl, C 1~4 Haloalkyl and C 1~4 alkoxy.

[0157] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] and Each R 12 are halo, hydroxy, amino, methylamino, dimethylamino, cyano, C 1~4 Alkyl, C 1~4 Haloalkyl and C 1~4 alkoxy.

[0158] In some embodiments of any one of Formula I, Formulas Ia-Ic, and Formula II, each R 12 are halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 In some embodiments, each R 12 is halo, C 1~4 Alkyl, C 1~4Alkoxy, C 1~4 Haloalkyl and OR 14 In some embodiments, each R 12 are halo, hydroxy, amino, methylamino, dimethylamino, cyano, C 1~4 Alkyl, C 1~4 Haloalkyl and C 1~4 In some embodiments, each R 12 is halo, C 1~4 Alkyl, C 1~4 Alkoxy and C 1~4 haloalkyl. In some embodiments, each R 12 are independently selected from the group consisting of F, Cl, Br, CH3, OCH3, and CF3.

[0159] In some embodiments of any one of Formula I, Formulas Ia-Ic, and Formula II, each R 12 is F, Cl, Br, CH3, OCH3, CF3, [ka] are independently selected from the group consisting of:

[0160] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] and Each R 12 are halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 R 14 is as defined and described herein.

[0161] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] and Each R 12 is halo, C 1~4 Alkyl, C 1~4 Alkoxy and C 1~4 haloalkyl. In some embodiments, each R 12 is independently selected from the group consisting of F, Cl, Br, CH3, OCH3, and CF3. In some embodiments, each R 12 is Cl.

[0162] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] and Each R 12 is halo, C 1~4 Alkyl, C 1~4 Alkoxy and C 1~4 haloalkyl. In some embodiments, each R 12 is independently selected from the group consisting of F, Cl, Br, CH3, OCH3, and CF3. In some embodiments, each R 12 are independently Cl or Br.

[0163] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R 14 is C 6~10 aryl and 5-10 membered heteroaryl, each of which is optionally C 1~4 Alkylamide, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4In some embodiments, R is substituted with one or more groups independently selected from the group consisting of: 14 is C 6~10 aryl and 5-10 membered heteroaryl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 In some embodiments, R is substituted with one or two groups independently selected from the group consisting of alkyl. 14 is C 6~10 aryl and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of halo, hydroxy, cyano, and C 1~4 and substituted with one or two groups independently selected from the group consisting of alkyl.

[0164] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R 14 is independently phenyl or a 5-6 membered heteroaryl having 1 to 4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 In some embodiments, R is substituted with one or more groups independently selected from the group consisting of: 14 is independently phenyl or a 5-6 membered heteroaryl having 1 to 4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 In some embodiments, R is substituted with one or two groups independently selected from the group consisting of alkyl. 14is independently phenyl, or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally selected from halo, hydroxy, cyano, and C 1~4 and substituted with one or two groups independently selected from the group consisting of alkyl.

[0165] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R 14 is phenyl or pyrazolyl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 In some embodiments, R is substituted with one or two groups independently selected from the group consisting of alkyl. 14 is phenyl, and optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 In some embodiments, R is substituted with one or two groups independently selected from the group consisting of alkyl. 14 is C 1~4 In some embodiments, R is a phenyl substituted with an alkylamide. 14 is phenyl substituted with -C(O)NHMe. In some embodiments, R 14 is phenyl. In some embodiments, R 14 is pyrazolyl, and optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 In some embodiments, R is substituted with one or two groups independently selected from the group consisting of alkyl. 14 is C 1~4 In some embodiments, R is a pyrazolyl substituted with alkyl. 14 is pyrazolyl substituted with methyl. In some embodiments, R 14 is N-methylpyrazolyl. In some embodiments, R 14 is pyrazolyl.

[0166] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] is represented by Each R 12 are halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and C 1~4 R is independently selected from the group consisting of: 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 and substituted with one or two groups independently selected from the group consisting of alkyl.

[0167] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] is represented by Each R 12 is halo, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 R 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 and substituted with one or two groups independently selected from the group consisting of alkyl.

[0168] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] is represented by Each R 12 is halo, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 R 14 is selected from the group consisting of phenyl and pyrazolyl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 and substituted with one or two groups independently selected from the group consisting of alkyl.

[0169] In some embodiments of any one of Formula I, Formula Ia-Ic, and Formula II, R1 is [ka] is represented by Each R 12 is halo, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 R 14 is phenyl, C 1~4 Alkylamide substituted phenyl, pyrazolyl, and C 1~4 In some embodiments, each R is selected from the group consisting of pyrazolyl substituted with alkyl. 12 is independently selected from the group consisting of F, Cl, Br, CH3, OCH3, and CF3; R 14 is selected from the group consisting of phenyl, MeNHC(O)-phenyl, pyrazolyl, and N-methylpyrazolyl. In some embodiments, each R 12 is Cl, and R 14 is selected from the group consisting of phenyl, MeNHC(O)-phenyl, pyrazolyl, and N-methylpyrazolyl.

[0170] In certain embodiments, the compound has formula II [ka] A compound represented by the formula: R1 is phenyl or pyridyl, each of which is 0 to 3 R 12 is replaced by Each R 12 Halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 are independently selected from the group consisting of R6 is amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino; R7 is selected from the group consisting of hydrogen, cyano, amido, halo, and hydroxy, or R7 is C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy; R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, and C 3~8 cycloalkyl; and R 14 is phenyl or pyrazolyl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4substituted by one or two groups independently selected from the group consisting of alkyl; The compound is a salt, an ester, or a prodrug thereof.

[0171] In certain embodiments, the compound has formula III [ka] A compound represented by the formula: R1 is phenyl or pyridyl, each of which is 0 to 3 R 12 is replaced by Each R 12 Halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 are independently selected from the group consisting of R6 is amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino; R7 is selected from the group consisting of hydrogen, cyano, amido, halo, and hydroxy, or R7 is C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 substituted with 1 to 3 substituents independently selected from the group consisting of alkoxy; R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, and C 3~8 cycloalkyl; and R 14is phenyl or pyrazolyl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 substituted by one or two groups independently selected from the group consisting of alkyl; The compound is a salt, an ester, or a prodrug thereof.

[0172] In certain embodiments, the compound has formula IV [ka] A compound represented by the formula: R1 is phenyl or pyridyl, each of which is 0 to 3 R 12 is replaced by Each R 12 Halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 are independently selected from the group consisting of R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, and C 3~8 cycloalkyl; R 14 is phenyl or pyrazolyl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 substituted with one or two groups independently selected from the group consisting of alkyl, Each R a Amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4aminoalkyl, The compound is a salt, an ester, or a prodrug thereof.

[0173] In certain embodiments, the compound has the formula V [ka] A compound represented by the formula: R1 is phenyl or pyridyl, each of which is 0 to 3 R 12 is replaced by Each R 12 Halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 and R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, and C 3~8 cycloalkyl; R 14 is phenyl or pyrazolyl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 substituted with one or two groups independently selected from the group consisting of alkyl, R a Amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 alkoxy, The compound is a salt, an ester, or a prodrug thereof.

[0174] In certain embodiments, the compound has formula VI [ka] A compound represented by the formula: R1 is phenyl or pyridyl, each of which is 0 to 3 R 12 is replaced by Each R 12 Halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 and R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, and C 3~8 cycloalkyl; R 14 is phenyl or pyrazolyl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 substituted with one or two groups independently selected from the group consisting of alkyl, Each R a Amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 independently selected from the group consisting of alkoxy, The compound is a salt, an ester, or a prodrug thereof.

[0175] In certain embodiments, the compound has formula VII [ka] A compound represented by the formula: R1 is phenyl or pyridyl, each of which is 0 to 3 R 12 is replaced by Each R 12 Halo, hydroxy, C 1~4 Alkyl, C 1~4Alkoxy, C 1~4 Haloalkyl and OR 14 and R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, and C 3~8 cycloalkyl; R 14 is phenyl or pyrazolyl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 substituted with one or two groups independently selected from the group consisting of alkyl, Each R a Amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 independently selected from the group consisting of alkoxy; The compound is a salt, an ester, or a prodrug thereof.

[0176] In certain embodiments, the compound has formula VIII [ka] A compound represented by the formula: R1 is phenyl or pyridyl, each of which is 0 to 3 R 12 is replaced by Each R1 is halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 and R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6Dihydroxyalkyl, and C 3~8 cycloalkyl; R 14 is phenyl or pyrazolyl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 substituted with one or two groups independently selected from the group consisting of alkyl, Each R a Amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 independently selected from the group consisting of alkoxy, The compound is a salt, an ester, or a prodrug thereof.

[0177] In certain embodiments, the compound has formula IX [ka] A compound represented by the formula: R1 is phenyl or pyridyl, each of which is 0 to 3 R 12 is replaced by Each R 12 Halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 and R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, and C 3~8 cycloalkyl; R 14 is phenyl or pyrazolyl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4substituted with one or two groups independently selected from the group consisting of alkyl, R a Amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 alkoxy, The compound is a salt, an ester, or a prodrug thereof.

[0178] In certain embodiments, the compound has the formula X [ka] A compound represented by the formula: R1 is phenyl or pyridyl, each of which is 0 to 3 R 12 is replaced by Each R 12 Halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 and R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, and C 3~8 cycloalkyl; R 14 is phenyl or pyrazolyl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 substituted with one or two groups independently selected from the group consisting of alkyl, Each R a Amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C1~4 Alkylamino, and C 1~4 aminoalkyl, The compound is a salt, an ester, or a prodrug thereof.

[0179] In certain embodiments, the compound has formula XI [ka] A compound represented by the formula: R1 is phenyl or pyridyl, each of which is 0 to 3 R 12 is replaced by Each R 12 Halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 and R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, and C 3~8 cycloalkyl; R 14 is phenyl or pyrazolyl, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 substituted with one or two groups independently selected from the group consisting of alkyl, Each R a Amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 aminoalkyl, The compound is a salt, an ester, or a prodrug thereof.

[0180] In some embodiments of any one of Formulas II-XI, R1, R6, R7, R 12 , R 13 , and R 14 may have the meaning set forth in any one or more of the above selected embodiments.

[0181] In some embodiments of any one of Formulas II-XI, R 13 is hydrogen, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, and C 3~8 In some embodiments, R is selected from the group consisting of cycloalkyl. 13 is hydrogen, halo, C 1~6 Alkyl, and C 1~6 In some embodiments, R is selected from the group consisting of haloalkyl. 13 is hydrogen, halo, C 1~4 Alkyl, and C 1~4 In some embodiments, R is selected from the group consisting of haloalkyl. 13 is selected from the group consisting of hydrogen, Cl, Br, methyl, and CF. In some embodiments, R 13 is hydrogen. In some embodiments, R 13 is Cl. In some embodiments, R 13 is Br. In some embodiments, R 13 is methyl. In some embodiments, R 13 is CF3.

[0182] In some embodiments of any one of Formulas II-XI, R1 is phenyl or pyridyl, each of which has 1 to 3 R 12 In some embodiments, R is phenyl or pyridyl, each of which is substituted with 2 or 3 R 12 In some embodiments, R is substituted with two or three R 12In some embodiments, R is phenyl substituted with two R 12 In some embodiments, R is phenyl substituted with three R 12 In some embodiments, R is phenyl substituted with two R 12 and pyridyl substituted with

[0183] In some embodiments of any one of Formulas II-XI, each R 12 is halo, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and OR 14 In some embodiments, each R 12 are halo, hydroxy, amino, methylamino, dimethylamino, cyano, C 1~4 Alkyl, C 1~4 Haloalkyl and C 1~4 In some embodiments, each R 12 is halo, C 1~4 Alkyl, C 1~4 Alkoxy and C 1~4 haloalkyl. In some embodiments, each R 12 are independently selected from the group consisting of F, Cl, Br, CH3, OCH3, and CF3.

[0184] In some embodiments of any one of Formulas II-XI, each R 12 is F, Cl, Br, CH3, OCH3, CF3, [ka] are independently selected from the group consisting of:

[0185] In some embodiments of any one of formulas II-XI, R1 is selected from the group consisting of two R 12 and each R 12 is independently selected from the group consisting of F, Cl, Br, CH3, OCH3, and CF3. In some embodiments, R1 is selected from two R12 and each R 12 is Cl.

[0186] In some embodiments of any one of formulas II-XI, R1 is selected from the group consisting of three R 12 and each R 12 is F, Cl, Br, CH3, OCH3, CF3, [ka] In some embodiments of any one of formulas II-XI, R1 is independently selected from the group consisting of: 12 and the first and second R 12 are Cl, and the third R 12 is Br. In some embodiments, R1 is selected from the group consisting of three R 12 and the first and second R 12 are Cl, and the third R 12 teeth [ka] is selected from the group consisting of:

[0187] In some embodiments of any one of Formulas II-XI, in some embodiments, R 14 is phenyl, and optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 In some embodiments, R is substituted with one or two groups independently selected from the group consisting of alkyl. 14 is C 1~4 In some embodiments, R is a phenyl substituted with an alkylamide. 14 is phenyl substituted with -C(O)NHMe. In some embodiments, R 14 is phenyl. In some embodiments, R 14 is pyrazolyl, and optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4In some embodiments, R is substituted with one or two groups independently selected from the group consisting of alkyl. 14 is C 1~4 In some embodiments, R is a pyrazolyl substituted with alkyl. 14 is pyrazolyl substituted with methyl. In some embodiments, R 14 is N-methylpyrazolyl. In some embodiments, R 14 is pyrazolyl.

[0188] In some embodiments of Formula II or Formula III, R6 is amino or C 1~4 In certain embodiments, R6 is amino. In certain embodiments, R6 is aminoalkyl. In certain embodiments, R6 is amino or aminomethyl. In certain embodiments, R6 is amino. In certain embodiments, R6 is aminomethyl.

[0189] In some embodiments of Formula II or Formula III, R7 is hydroxy, C 1~4 Alkyl or C 1~4 In certain embodiments, R7 is C 1~4 In certain embodiments, R7 is alkyl. In certain embodiments, R7 is methyl. In certain embodiments, R7 is ethyl.

[0190] In some embodiments of Formula II or Formula III, R6 is amino and R7 is C 1~4 In certain embodiments, R6 is amino and R7 is methyl. In some embodiments, R6 is amino and R7 is ethyl. In some embodiments, R6 is aminomethyl and R7 is C 1~4 In certain embodiments, R6 is aminomethyl and R7 is methyl.

[0191] In some embodiments of any one of Formulas IV-XI, each R a are amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy and C 1~4 haloalkyl. In some embodiments, each Ra are independently amino or C 1~4 In some embodiments, each R a is independently amino or methyl.

[0192] In some embodiments, the compound is [ka] [ka] [ka] The compound is represented by a formula selected from the group consisting of:

[0193] Also provided are embodiments in which any one or more of these embodiments may be combined with any of the embodiments described above, provided that the combinations are not mutually exclusive.

[0194] As used herein, two embodiments are "mutually exclusive" when one embodiment is defined as something different from the other embodiment.For example, the embodiment in which two groups are joined together to form a cycloalkyl is mutually exclusive with the embodiment in which one group is ethyl and the other group is hydrogen.Similarly, the embodiment in which one group is CH2 is mutually exclusive with the embodiment in which the same group is NH.

[0195] Compounds selected from the examples disclosed herein are also provided.

[0196] IV. Composition Also provided are pharmaceutical compositions comprising a compound disclosed herein in association with a pharma- ceutically acceptable carrier.

[0197] In certain embodiments, the pharmaceutical composition is formulated for oral administration.

[0198] In certain embodiments, the pharmaceutical composition is formulated for parenteral administration.

[0199] In certain embodiments, the pharmaceutical composition is formulated for intravenous administration.

[0200] In certain embodiments, the pharmaceutical composition is formulated for subcutaneous administration.

[0201] In certain embodiments, the oral pharmaceutical composition is selected from tablets and capsules.

[0202] While the compounds of the subject invention may be administered as the raw chemical, they may also be provided as pharmaceutical formulations. Thus, there are provided pharmaceutical formulations comprising one or more of certain compounds disclosed herein, or one or more pharma- ceutically acceptable salts, esters, prodrugs, amides, or solvates of those compounds, together with one or more pharma- ceutically acceptable carriers of the pharmaceutical formulation and, optionally, one or more other therapeutic ingredients. The carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient of the formulation. Proper formulation will depend on the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as appropriate and as understood in the art. These pharmaceutical compositions disclosed herein may be manufactured by any method known in the art, for example, by conventional mixing, dissolving, granulating, dragee-making, wet-milling, emulsifying, encapsulating, entrapping, or tabletting processes.

[0203] The formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intraosseous), intraperitoneal, transmucosal, transdermal, rectal, and topical (including dermal, buccal, sublingual, and ocular) administration, although the most suitable route may depend on the condition and disability of the recipient. The formulations may conveniently be provided in unit dosage form and may be prepared by any of the methods well known in the pharmaceutical art. These methods typically include the step of bringing into association a compound of the subject invention or a pharma-ceutically acceptable salt, ester, amide, prodrug, or solvate thereof ("active ingredient") with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers, or both, and then, if necessary, shaping the product into the desired formulation.

[0204] Formulations of the compounds disclosed herein suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, each containing a predetermined amount of the active ingredient, as a powder or granules, as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary, or paste.

[0205] Pharmaceutical preparations that can be used orally include tablets, push-fit capsules made of gelatin, and soft sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, inert diluent, or lubricant, surfactant, or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may be optionally coated or grooved and may be formulated so as to provide a delayed or controlled release of the active ingredient therein. All preparations intended for oral administration should be in a suitable form for such administration. The push-fit capsules may contain the active ingredient in admixture with a filler such as lactose, a binder such as starch, and / or a lubricant such as talc or magnesium stearate, and optionally stabilizers. In soft capsules, the active compound may be dissolved or suspended in a suitable liquid, such as fatty oils, liquid paraffin, or liquid polyethylene glycol. Also, stabilizers may be added. Dragee cores are provided with a suitable coating. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and / or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyes or pigments may be added to tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0206] The compounds may be formulated for parenteral administration by injection, e.g., bolus injection or continuous infusion. The formulations for injection may be provided in unit dosage form, such as in ampoules or multi-dose containers, with added preservatives. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents, such as suspending, stabilizing, and / or dispersing agents. The formulations may be provided in unit-dose or multi-dose containers, such as sealed ampoules and vials, and may be stored in powder or freeze-dried (lyophilized) form requiring only the addition of a sterile liquid carrier, e.g., saline or sterile pyrogen-free water, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets of the kind previously described.

[0207] Preparations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compound, which may contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, as well as aqueous and non-aqueous sterile suspensions, which may contain suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may contain suitable stabilizers or agents that increase the solubility of the compound, allowing for the preparation of highly concentrated solutions.

[0208] In addition to the formulations described above, the compounds may be formulated as depot preparations. Such long-acting formulations may be administered by implantation (such as subcutaneous or intramuscular implantation) or intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (e.g., as an emulsion in an acceptable oil), or with ion exchange resins, or may be formulated as sparingly soluble derivatives, such as a sparingly soluble salt.

[0209] For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, pastilles, or gels formulated in a conventional manner. Such compositions may contain the active ingredient in a flavored base, such as sucrose and gum acacia or gum tragacanth.

[0210] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, eg, containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.

[0211] Certain compounds disclosed herein may be administered locally, meaning by non-systemic administration. This includes applying the compounds disclosed herein externally to the epidermis or oral cavity, so that the compounds do not enter the bloodstream as much, and injecting such compounds into the ear, eye, and nose. In contrast, systemic administration refers to oral administration, intravenous administration, intraperitoneal administration, and intramuscular administration.

[0212] Suitable formulations for topical administration include liquid or semi-liquid formulations such as gels, liniments, lotions, creams, ointments, or pastes suitable for penetration through the skin to the site of inflammation, and drops suitable for administration to the eye, ear, or nose. For topical administration, the active ingredient may, for example, comprise 0.001% to 10% (wt%) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% wt. In other embodiments, the active ingredient may comprise less than 5% wt. In certain embodiments, the active ingredient may comprise 2% to 5% wt. In other embodiments, the active ingredient may comprise 0.1% to 1% wt.

[0213] For administration by inhalation, the compound may be conveniently delivered from an insufflator, a nebulizer pressurized pack, or other convenient means of delivery of an aerosol spray. The pressurized pack may contain a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compound of the present invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base, such as lactose or starch. The powder composition may be presented in unit dosage form in capsules, cartridges, gelatin packs, or blister packs from which the powder can be administered with the aid of an inhaler or insufflator.

[0214] Preferred unit dosage forms are those containing an effective dose of the active ingredients, as hereinbelow recited, or an appropriate fraction thereof.

[0215] It should be understood that the formulations described above may include, in addition to the ingredients particularly mentioned above, other agents conventional in the art having regard to the type of formulation in question; for example, formulations suitable for oral administration may include flavoring agents.

[0216] The compounds may be administered orally or by injection at a daily dose of 0.1 to 500 mg / kg. For adult humans, this range is typically from 5 mg / day to 2 g / day. Tablets, or dosage forms provided in discrete units, may conventionally contain one or more compounds in amounts effective at such doses, or in amounts that are multiples of such amounts, and may include units containing, for example, 5 mg to 500 mg, usually about 10 mg to 200 mg.

[0217] The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

[0218] V. Method The present invention also relates to a method of inhibiting at least one PTPN11 function, comprising contacting PTPN11 with a compound described herein. Cell phenotype, cell proliferation, activity of PTPN11, changes in biochemical production caused by active PTPN11, expression of PTPN11, or binding of PTPN11 to natural binding partners can be monitored. Such methods can be disease treatment modes, biological assays, cellular assays, biochemical assays, etc.

[0219] The present specification also provides a method for treating a PTPN11 mediated disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a salt or tautomer thereof.

[0220] In certain embodiments, the disease is cancer.

[0221] In certain embodiments, the cancer is selected from breast cancer, colon cancer, leukemia, or melanoma.

[0222] The present specification also provides a method for treating a PTP-mediated disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound disclosed herein, or a salt or tautomer thereof.

[0223] In certain embodiments, the disease is selected from Noonan Syndrome and Leopard Syndrome.

[0224] In certain embodiments, the disease is cancer.

[0225] In certain embodiments, the cancer is selected from breast cancer, colon cancer, leukemia, or melanoma.

[0226] The present specification also provides compounds disclosed herein for use as pharmaceutical agents.

[0227] The present specification also provides compounds disclosed herein for use as medicaments for the treatment of PTPN11 mediated diseases.

[0228] The present specification also provides the compounds disclosed herein for use as pharmaceutical agents for the treatment of PTP-mediated diseases.

[0229] There is also provided the use of the compounds disclosed herein as pharmaceutical agents.

[0230] Also provided is the use of the compounds disclosed herein as pharmaceutical agents for the treatment of PTPN11-mediated diseases.

[0231] Also provided is a compound disclosed herein for use in the manufacture of a medicament for the treatment of a PTPN11 mediated disease.

[0232] Use of the compounds disclosed herein for the treatment of a PTPN11-mediated disease is also provided.

[0233] Also provided is the use of the compounds disclosed herein for the treatment of a PTP-mediated disease.

[0234] The present specification also provides a method of inhibiting PTPN11, comprising contacting PTPN11 with a compound disclosed herein, or a salt or tautomer thereof.

[0235] Also provided herein are methods of inhibiting a PTP comprising contacting the PTP with a compound disclosed herein, or a salt or tautomer thereof.

[0236] The present specification also provides a method for obtaining an effect in a patient, comprising administering to said patient a therapeutically effective amount of a compound disclosed herein, or a salt or tautomer thereof, wherein said effect is cognitive enhancement.

[0237] In certain embodiments, the PTPN11-mediated disorder is selected from Noonan Syndrome and Leopard Syndrome.

[0238] In certain embodiments, the PTPN11-mediated disease is cancer.

[0239] In certain embodiments, the PTPN11-mediated disease is selected from breast cancer, colon cancer, leukemia, or melanoma.

[0240] Also provided are methods for modulating PTPN11-mediated function in a subject comprising administering a therapeutically effective amount of a compound disclosed herein.

[0241] Administration and Combination Therapy The compound can be administered in various modes, for example, orally, topically, or by injection. The exact amount of compound administered to a patient is the responsibility of the attending physician. The specific dose level for any particular patient depends on a variety of factors, including the activity of the particular compound used, age, body weight, general health, sex, diet, administration time, administration route, excretion rate, concomitant medications, the exact disorder being treated, and the severity of the indication or condition being treated. Also, the administration route may vary depending on the condition and its severity.

[0242] In certain instances, it may be appropriate to administer at least one of the compounds described herein (or a pharma- ceutically acceptable salt, ester, tautomer, or prodrug thereof) in combination with another therapeutic agent. By way of example only, if hypertension is one of the side effects experienced by a patient upon receiving one of the compounds herein, it may be appropriate to administer an antihypertensive agent in combination with the first therapeutic agent. Alternatively, by way of example only, the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjunct (i.e., the adjunct itself may only have minimal therapeutic effect, but when combined with another therapeutic agent, the overall therapeutic effect on the patient is enhanced). Alternatively, by way of example only, the effect obtained by the patient may be enhanced by administration of one of the compounds described herein with another therapeutic agent (including an optimal treatment regimen) that also has a therapeutic effect. By way of example only, a treatment for diabetes that includes administration of one of the compounds described herein may have an increased therapeutic effect by also administering another therapeutic agent for diabetes to the patient. In any case, regardless of the disease, disorder, or condition being treated, the overall effect the patient experiences may be a simple sum of the two therapeutic agents, or the patient may experience a synergistic effect.

[0243] Specific non-limiting examples of potential combination therapies include the use of certain compounds of the invention in combination with anti-cancer drugs (chemotherapeutic agents) including, but not limited to, classes of anti-cancer drugs such as alkylating agents, antimetabolites, antimitotic agents, checkpoint inhibitors, plant alkaloids and terpenoids, topoisomerase inhibitors, cytotoxic antibiotics, aromatase inhibitors, angiogenesis inhibitors, anti-steroids and anti-androgens, mTOR inhibitors, tyrosine kinase inhibitors, and others.

[0244] For use in cancer and neoplastic diseases, PTPN11 (SHP2) inhibitors may be most desirably combined with one or more of the following non-limiting examples of anti-cancer agents: (1) Alkylating agents, including, but not limited to, carmustine, chlorambucil (Leukeran), cisplatin (Platin), carboplatin (Paraplatin), oxaliplatin (Eloxatin), streptozocin (Zanosar), busulfan (Myleran), dacarbazine, ifosfamide, lomustine (CCNU), melphalan (Alkeran), procarbazine (MATULAN), temozolomide (TEMODAR), thiotepa, and cyclophosphamide (Endoxan). (2) Antimetabolites, including but not limited to cladribine (Leustatin), mercaptopurine (Prinetol), thioguanine, pentostatin (Nipent), cytosine arabinoside (cytarabine, ARA-C), gemcitabine (Gemzar), fluorouracil (5-FU, CARAC), capecitabine (Xeloda), leucovorin (FUSILEV), methotrexate (Rheumatrex), and raltitrexed. (3) Antimitotic agents, including but not limited to taxanes such as docetaxel (TAXITERE) and paclitaxel (Abraxane, Taxol), and vinca alkaloids such as vincristine (Oncovin), vinblastine, vindesine, and vinorelbine (Navelbine), which are often plant alkaloids and terpenoids, or derivatives thereof. (4) Checkpoint inhibitors, such as the anti-PD-1 or anti-PD-L1 antibodies pembrolizumab (Keytruda), nivolumab (Opdivo), MEDI4736, and MPDL3280A, the anti-CTLA-4 antibody ipilimumab (Yervoy), and antibodies targeting LAG3 (lymphocyte-activation gene 3 protein), KIR (killer cell immunoglobulin-like receptor), 4-1BB (tumor necrosis factor receptor superfamily member 9), TIM3 (T-cell immunoglobulin mucin domain-containing protein 3), and OX40 (tumor necrosis factor receptor superfamily member 4). (5) Topoisomerase inhibitors, including but not limited to camptothecin (CTP), irinotecan (Camptosar), topotecan (Hycamtin), teniposide (VUMON), and etoposide (EPOSIN). (6) Cytotoxic antibiotics, including, but not limited to, actinomycin D (Dactinomycin, Cosmegen), bleomycin (Blenoxane), doxorubicin (Adriamycin), daunorubicin (Cerbidine), epirubicin (Elence), fludarabine (Fludara), idarubicin, mitomycin (MITOSOL), mitoxantrone (Novantrone), and plicamycin. (7) Aromatase inhibitors, including but not limited to aminoglutethimide, anastrozole (Arimidex), letrozole (Femara), vorozole (RIVIZOR), and exemestane (Aromasin). (8) Angiogenesis inhibitors, including but not limited to genistein, sunitinib (Sutent), and bevacizumab (Avastin). (9) Antisteroids and antiandrogens such as aminoglutethimide (Citadren), bicalutamide (Casodex), cyproterone, flutamide (Eurexin), and nilutamide (Nilandrone). (10) Tyrosine kinase inhibitors, including but not limited to imatinib (Gleevec), erlotinib (Tarceva), lapatinib (Tykerb), sorafenib (Nexavar), and axitinib (Inlyta). (11) mTOR inhibitors such as everolimus, temsirolimus (Torisel), and sirolimus. (12) Monoclonal antibodies such as trastuzumab (Herceptin) and rituximab (Rituxan). (13) Other medications, such as amsacrine, Bacille Calmette-Guerin (BCG) vaccine; buserelin (ETILAMIDE); chloroquine (ARALEN); clodronate, pamidronate, and other bisphosphonates; colchicine; demethoxyviridine; dichloroacetic acid; estramustine; filgrastim (Neupogen); fludrocortisone (Florinef); goserelin (Zoladex); interferon; leucovorin; leuprolide (Leupron); levamisole; lonidamine; mesna; metformin; mitotamine steroids such as fluoxymesterone (Halotestin); estrogens such as estradiol, diethylstilbestrol (DES), and dienestrol; progestins such as medroxyprogesterone acetate (MPA) and megestrol; and testosterone.

[0245] In any case, the multiple therapeutic agents (at least one of which is a compound disclosed herein) may be administered in any order or simultaneously. If administered simultaneously, the multiple therapeutic agents may be provided in a single, integrated form or in multiple forms (by way of example only, administered as a single pill or as two separate pills). One of the therapeutic agents may be administered in multiple doses or both may be administered as multiple doses. If not administered simultaneously, the timing between the multiple administrations may range anywhere from a few minutes to four weeks.

[0246] Accordingly, in another aspect, certain embodiments provide a method for treating a PTPN11-mediated disorder in a human or animal subject in need thereof, comprising administering an amount of a compound disclosed herein together with at least one additional agent known in the art for treating said disorder effective to alleviate or prevent said disorder in said subject. In a related aspect, certain embodiments provide a therapeutic composition comprising at least one compound disclosed herein in combination with one or more additional agents for treating a PTPN11-mediated disorder.

[0247] In some embodiments, the methods described herein are used comprising administering a therapeutically effective amount of a compound of Formula I, or a pharma- ceutically acceptable salt thereof, to a subject in need thereof to treat a disease condition, which condition is cancer that has developed resistance to chemotherapeutic agents and / or ionizing radiation.

[0248] In some embodiments, the methods described herein are used comprising administering a therapeutically effective amount of a compound of Formula I, or a pharma- ceutically acceptable salt thereof, to a subject in need thereof to treat a disease condition, which condition is cancer that has developed resistance to chemotherapeutic agents and / or ionizing radiation.

[0249] The compounds, compositions, and methods disclosed herein are useful for treating diseases. In certain embodiments, the disease is one of abnormal cell proliferation, including cancer. The cancer may be hormone-dependent or hormone-independent, such as in the case of breast cancer. In certain embodiments, the cancer is a solid tumor. In other embodiments, the cancer is a lymphoma or leukemia. In certain embodiments, the cancer is a drug-resistant cancer disclosed herein or known in the art. Tumor invasion, tumor growth, tumor metastasis, and angiogenesis may also be treated using the compositions and methods disclosed herein. Precancerous neoplasms may also be treated using the compositions and methods disclosed herein.

[0250] Cancers that may be treated by the methods disclosed herein include colorectal, breast, ovarian, lung, and prostate cancer, cancer of the oral cavity and pharynx (lips, tongue, mouth, larynx, pharynx), esophageal, gastric, small intestine, colorectal, colon, rectal, liver, and biliary tract cancer; pancreatic, bone, connective tissue, skin, cervical, uterine, endometrial, testicular, bladder, kidney, and other urinary tract tissues, including renal cell carcinoma (RCC), eye, brain, spinal cord, and other components of the central peripheral nervous system and associated structures such as the meninges, and thyroid and other endocrine glands. The term "cancer" also includes cancers that do not necessarily form solid tumors, including hematopoietic malignancies, including Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, and leukemias (chronic lymphocytic leukemia (CLL), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML)), and lymphomas, including lymphocytic lymphoma, granulocytic lymphoma, and monocytic lymphoma. Other types of cancer that may be treated using the compounds and methods of the invention include adenocarcinoma, angiosarcoma, astrocytoma, acoustic neuroma, anaplastic astrocytoma, basal cell carcinoma, glioblastoma, chondrosarcoma, choriocarcinoma, chondroma, craniopharyngioma, cutaneous melanoma, cystadenocarcinoma, endothelial sarcoma, embryonal carcinoma, ependymoma, Ewing's tumor, epithelial carcinoma, fibrosarcoma, gastric cancer, genitourinary tract cancer, glioblastoma multiforme, head and neck cancer, hemangioblastoma, hepatocellular carcinoma, liver cancer, Kaposi's sarcoma, large cell carcinoma, leiomyosarcoma, leukemia, liposarcoma, lymphatic system cancer, lymphoma, lymphangiosarcoma These include, but are not limited to, lymphangiosarcoma, medullary thyroid carcinoma, medulloblastoma, meningioma mesothelioma, myeloma, myxosarcoma neuroblastoma, neurofibrosarcoma, oligodendroglioma, osteogenic sarcoma, epithelial ovarian carcinoma, papillary carcinoma, papillary adenocarcinoma, paraganglioma, parathyroid tumor, pheochromocytoma, pinealoma, plasmacytoma, retinoblastoma, rhabdomyosarcoma, sebaceous gland carcinoma, seminoma, skin cancer, melanoma, small cell lung carcinoma, non-small cell lung carcinoma, squamous cell carcinoma, sweat gland carcinoma, synovioma, thyroid carcinoma, uveal melanoma, and Wilms' tumor.

[0251] In certain embodiments, the compositions and methods disclosed herein are useful for preventing or inhibiting tumor invasion and metastasis.

[0252] Certain compounds and formulations disclosed herein are useful for human treatment and may also be useful for veterinary treatment of companion animals, exotic animals, and farm animals, including mammals, rodents, etc. More preferred animals include horses, dogs, and cats.

[0253] VI. Preparation method The chirality of the molecule is described using the descriptors R and S for central chirality and R for axial chirality. a and S a PAC 1996, 68, 2193; Basic terminology of stereochemistry (IUPAC Recommendations 1996), doi:10.1351 / pac199668122193; Preferred IUPAC Names, Chapter 9, September 2004; Cahn, CK Ingold, and V. Prelog, Angew. Chem. Internat. Ed. Eng. 5, 385-415, 511 (1966); V. Prelog and G. Helmchen, Angew. Chem. Internat. Ed. Eng. 21, 567-583 (1982).

[0254] Synthesis scheme The following schemes can be used to practice the present invention.

[0255] Overview of synthetic methods for preparing compounds The following schemes can be used as a general guide for preparing the compounds of the present invention.

[0256] Abbreviation table Pd2dba3 = tris(dibenzylideneacetone)dipalladium, Xantphos = 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene, HCl = hydrogen chloride, TFA = trifluoroacetic acid, POCl3 = phosphorus(V) oxychloride, Tf2O = trifluoromethanesulfonic anhydride, DIEA = diisopropylethylamine, DCM = dichloromethane, BOP = (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate), DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, NBS = N-bromosuccinimide, and NCS = N-chlorosuccinimide. [ka]

[0257] The aryl halide A can be converted to the corresponding protected amine B using a "Pd" catalyst and ligand such as Pd2dba3 and Xantphos. Amine B can be deprotected to give C, and the corresponding acetimidamide D can be formed by treating amine C with acetonitrile and an acid such as HCl. Aryl-substituted-6-hydroxy-2-methylpyrimidin-4(3H)-one E can be formed by reacting D with the desired malonate to give E. E can be converted to the corresponding halide by treatment with reagents such as POCl3 or triflate with Tf2O and DIEA in DCM. A subsequent SNAr reaction can provide the protected amine G, which can be converted to the deprotected amine H. F can be directly converted to H in a SNAr reaction. Direct conversion of E to H can be achieved by application of reagents such as BOP and DBU. H can be further functionalized to the corresponding bromide, chloride, or CF3 derivative (I) by application of reagents such as NBS, NCS, or bis(((trifluoromethyl)sulfinyl)oxy)zinc in the presence of tert-butyl hydroperoxide. [ka]

[0258] The fluoronitrobenzene derivative J can be transferred to the corresponding ether K using an alcohol or phenol and a base such as sodium hydride under SNAr reaction conditions. This nitro derivative can be reduced to the amine L using a reducing agent such as SnCl2.2H2O. Compound L can then be converted to the desired pyrimidinone derivative M as illustrated in Scheme I.

[0259] It is understood that other synthetic routes may be available for practicing the present invention.

[0260] The invention is further illustrated by the following examples which can be synthesized and isolated as the free base or a salt, such as a TFA salt or HCl salt. EXAMPLES

[0261] VII. Working Examples Abbreviation table mg = milligrams, mL = milliliters, ul = microliters, M = molar, mmol = millimole, h = hours, min. = minutes, Rt = room temperature, N2 = nitrogen, HCl = hydrogen chloride, H2O = water, MS = mass spectrometry, ES+ = electrospray positive ionization, 1H-NMR = proton nuclear magnetic resonance, MHz = megahertz, DMSO-d6 = deuterated dimethyl sulfoxide (d6), H = hydrogen, rt = room temperature, °C = degrees Celsius, Br2 = bromine, NaOH = sodium hydroxide, NaHSO3 = sodium bisulfite, K2CO3 = potassium carbonate, NMP = N-methyl-2-pyrrolidone, BOP = (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate), DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, DIEA = diisopropylethylamine, MW = microwave, KF = potassium fluoride, Pd(dppf)Cl2 = [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride, Pd2dba3 = tris(dibenzylideneacetone)dipalladium , POCl3 = phosphorus(V) oxychloride, PE = petroleum ether, EA = ethyl acetate, CDCl3 = deuterated chloroform, MeOH = methanol, DO = deuterated water, HPLC = high performance liquid chromatography, DMSO = dimethylsulfoxide, MeCN (or ACN) = acetonitrile, NIS = N-iodosuccinimide, DMF = dimethylformamide, K3PO4 = tripotassium phosphate, Et2O = diethyl ether, EtOAc = ethyl acetate, EtOH = ethanol, NaOMe = sodium methoxide, NaOEt = sodium ethoxide, NCS = N-chlorosuccinimide, TBDMS = TBS = tert-butyldimethylsilyl, TFA = trifluoroacetic acid, DCM = dichloromethane, Xantphos = 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene.

[0262] Example 1 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one TFA salt [ka] Step 1: N-(2,3-dichlorophenyl)acetimidamide [ka] Method A To a mixture of 2,3-dichloroaniline (1.6 g, 10 mmol) and MeCN (615 mg, 15.0 mmol) in 1,2-dichloroethane (10 mL) was added AlCl3 (1.46 g, 1.10 mmol) at 0°C. The reaction mixture was stirred for 10 min, after which it was heated to 100°C in a sealed tube for 18 h. The reaction was cooled to room temperature, ice-cold water (30 mL) was added, and the aqueous phase was extracted with DCM (2 x 50 mL). Then 2 M NaOH was added to adjust the pH to 10, and the aqueous phase was extracted with DCM (3 x 50 mL). The combined organic layers were dried over MgSO4 and concentrated under reduced pressure to give the title compound as a beige oil (950 mg, 47%). MS (ES + ) C8H8Cl2N2 Calculated value: 202, Found value: 203 [M+H] + This product was used in the next step without further purification.

[0263] Method B HCl gas was bubbled through MeCN (123 mL) in a high pressure reaction vessel at 0° C. for 15 seconds to obtain a saturated solution. 2,3-Dichloroaniline (7.30 mL, 61.7 mmol) was added to form a white solid precipitate. The vessel was sealed and the mixture was heated at 120° C. for 16 hours. The reaction mixture was cooled to room temperature and the white precipitate was collected by vacuum filtration. The solid was washed with Et2O (3×20 mL) and dried under vacuum to give the title compound as a white solid (14.5 g, 98% yield). MS (ES + ) C8H8Cl2N2 Calculated value: 202, Found value: 203 [M+H] + .

[0264] Step 2: 3-(2,3-dichlorophenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one [ka] Method A To a solution of N-(2,3-dichlorophenyl)acetimidamide (950 mg, 4.68 mmol) in 2-methoxyethan-1-ol (10 mL) was added diethyl malonate (2.99 g, 18.7 mmol) and NaOMe in MeOH (4 M, 4.7 mL, 18 mmol). The mixture was heated at 120° C. for 16 h. The reaction mixture was cooled to room temperature, poured into water (50 mL), and extracted with Et2O (50 mL). The aqueous layer was acidified to about pH 2 with HCl (6 M, aq.) and the solid precipitate was collected by filtration to give the title compound as a white solid (1 g, 77%). MS (ES + ) C 11 H8Cl2N2O2 Calculated value: 270, Found value: 271 [M+H] + .

[0265] Method B To a suspension of N-(2,3-dichlorophenyl)acetimidamide (30 g, 125 mmol) in EtOH (125 mL) was added diethyl malonate (38.2 mL, 250 mmol) and NaOEt (20% in EtOH) (140 mL, 376 mmol), and the resulting mixture was stirred in a sealed tube at 120° C. for 18 h. The reaction mixture was allowed to cool to room temperature and the volatiles were removed under reduced pressure. To the residue was added water (30 mL), the mixture was cooled to 0° C., and the mixture was acidified to about pH 2 with HCl (6 M, aq.). The mixture was allowed to warm to room temperature and stirred for 1 h. The solid was collected by vacuum filtration, washed with Et2O (2×20 mL), and dried under reduced pressure to give the title compound as a tan solid (mixture of enantiomers) (26.3 g, 77%). MS (ES + ) C 11 H8Cl2N2O2 Calculated: 270, Found: 271 [M+H] + .

[0266] The compound in step 2 is 3-(S a )-(2,3-dichlorophenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one and 3-(R a)-(2,3-dichlorophenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one.

[0267] Step 3: 6-chloro-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one [ka] A mixture of 1-(2,3-dichlorophenyl)-2-methylpyrimidine-4,6(1H,5H)-dione (250 mg, 0.92 mmol) in POCl3 (5 mL) was heated at 100° C. for 4 h. The reaction mixture was cooled to room temperature, concentrated under reduced pressure, and added slowly to ice-cold water. The mixture was extracted with EtOAc (15 mL×3). The organic layer was dried and concentrated under reduced pressure. The residue was purified by flash column chromatography (EtOAc in PE, 20-50%) to give the title compound as a beige solid (100 mg, 37.5%) (mixture of enantiomers). MS (ES) + ) C 11 H7Cl3N2O Calculated: 288, Found: 289 [M+H] + .

[0268] The compound in step 3 is 6-chloro-3-(S a )-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one and 6-chloro-3-(R a )-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one.

[0269] Step 4: tert-Butyl (1-(1-(2,3-dichlorophenyl)-2-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-4-methylpiperidin-4-yl)carbamate [ka] A mixture of 6-chloro-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one (100 mg, 0.35 mmol), tert-butyl (4-methylpiperidin-4-yl)carbamate (89 mg, 0.42 mmol), and DIEA (134 mg, 1.04 mmol) in DMF (3 mL) was stirred at 100° C. for 3 h. The reaction mixture was diluted with water and extracted with EtOAc (15 mL×3). The organic layer was washed with brine, dried over MgSO4, and concentrated under reduced pressure to give the title compound. MS (ES) + ) C 22 H 28 Cl2N4O3 Calculated: 466, Found: 467 [M+H] + This product was used in the next step without further purification.

[0270] The compound in step 4 is tert-butyl (1-(1-(S a )-(2,3-dichlorophenyl)-2-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-4-methylpiperidin-4-yl)carbamate and tert-butyl (1-(1-(R a )-(2,3-dichlorophenyl)-2-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-4-methylpiperidin-4-yl)carbamate.

[0271] Step 5: 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one TFA salt To a solution of tert-butyl (1-(1-(2,3-dichlorophenyl)-2-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-4-methylpiperidin-4-yl)carbamate (0.35 mmol, crude product) in DCM (3 mL) was added TFA (1 mL). The resulting solution was stirred at room temperature for 2 h and concentrated under reduced pressure. The residue was purified by preparative HPLC (mobile phase: A=0.01% TFA / HO, B=MeCN; gradient: B=60% to 95% in 18 min; column: Venusil CBP C18 (L) C18, 10 um, 21.2 mm×250 mm, catalog number: VX902520-L) to give the title compound as a white solid (110 mg, 86%). MS (ES + ) C 17 H 20 Cl2N4O Calculated: 366, Found: 367 [M+ H] + . 1H NMR (500 MHz, DMSO) δ 8.03 (s, 3H), 7.80 (dd, J = 7.8, 1.7 Hz, 1H), 7.61 - 7.46 (m, 2H), 5.47 (s, 1H), 4.08 - 3.82 (m, 2H), 3.34 - 3.29 (m, 2H), 2.00 (s, 3H), 1.71 (t, J = 5.5 Hz, 4H), 1.37 (s, 3H).

[0272] The compound of Example 1 is 6-(4-amino-4-methylpiperidin-1-yl)-3-(S a )-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one TFA salt and 6-(4-amino-4-methylpiperidin-1-yl)-3-(R a )-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one TFA salt.

[0273] Examples 2a and 2b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a)-(2,3-Dichlorophenyl)-2-methylpyrimidin-4(3H)-one (Example 2a): [ka] 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2,3-Dichlorophenyl)-2-methylpyrimidin-4(3H)-one (Example 2b): [ka] To a suspension of 3-(2,3-dichlorophenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one (Example 1, step 2, 3.50 g, 12.9 mmol) and (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine dihydrochloride (3.45 g, 14.2 mmol) in MeCN (43 ml) was added DBU (6.23 mL, 41.3 mmol) and BOP (6.85 g, 15.5 mmol), and the resulting mixture was stirred at room temperature for 24 h. The mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (2-15% MeOH in DCM with 2% NH4OH) to give the title compound as a mixture of diastereomers as an off-white solid (4.2 g, 77% yield). This mixture of diastereomers was separated by chiral SFC (mobile phase: CO2 / methanol (0.25% isopropylamine) = 60 / 40; flow rate: 80 g / min; 5 min; column temperature: 25 °C; back pressure: 100 bar; column: ES Industries ChromegaChiral CCS, 2.0 x 25.0 cm) to give the title compounds Example 2a (19.7 g, 48%) as a white solid and Example 2b (11.6 g, 28%) as a white solid.

[0274] Example 2a 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a)-(2,3-Dichlorophenyl)-2-methylpyrimidin-4(3H)-one: MS (ES + ) C 20 H 24 Cl2N4O2 Calculated value: 422, Found value: 423 [M+H] + . 1 H NMR (600 MHz, CDCl3) δ 7.57 (dd, J = 8.1, 1.5 Hz, 1H), 7.35 (t, J = 8.0 Hz, 1H), 7.21 (dd, J = 7.9, 1.5 Hz, 1H), 5.45 (s, 1H), 4.21 - 4.16 (m, 1H), 3.86 (br s, 2H), 3.79 (d, J = 8.7 Hz, 1H), 3.68 (d, J = 8.7 Hz, 1H), 3.40 (ddd, J = 13.1, 9.1, 3.8 Hz, 1H), 3.31 (ddd, J = 13.3, 9.4, 3.2Hz, 1H), 2.98 (d, J = 4.5 Hz, 1H), 2.06 (s, 3H), 1.84 (ddd, J = 13.4, 9.4, 3.9 Hz, 1H), 1.75 - 1.60 (m, 3H), 1.23 (d, J = 6.4 Hz, 3H).

[0275] Example 2b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2,3-Dichlorophenyl)-2-methylpyrimidin-4(3H)-one: MS (ES + ) C 20 H 24 Cl2N4O2 Calculated: 422, Found: 423 [M+H] + . 1H NMR (600 MHz, CDCl3) δ 7.57 (dd, J = 8.2, 1.5 Hz, 1H), 7.36 (t, J = 8.0 Hz, 1H), 7.21 (dd, J = 7.9, 1.5 Hz, 1H), 5.46 (s, 1H), 4.22 - 4.14 (m, 1H), 3.95 - 3.82 (m, 2H), 3.80 (d, J = 8.7 Hz, 1H), 3.68 (d, J = 8.7 Hz, 1H), 3.45 - 3.36 (m, 1H), 3.29 (ddd, J = 13.3, 9.5, 3.3 Hz, 1H), 2.99 (d, J = 4.6 Hz, 1H), 2.07 (s, 3H), 1.84 (ddd, J = 13.4, 9.4, 3.9 Hz, 1H), 1.77 - 1.70 (m, 1H), 1.70 - 1.61 (m, 2H), 1.24 (d, J = 6.4 Hz, 3H).

[0276] The following examples were synthesized using methods similar to those used in Examples 1 and 2. In general, these examples can be made by the methods disclosed herein. These examples can be made as the free base or as a TFA salt. [Table 1-1] [Table 1-2] [Table 1-3]

[0277] The compound of Example 3 is 6-[4-(aminomethyl)-4-methylpiperidin-1-yl]-3-(S a )-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one and 6-[4-(aminomethyl)-4-methylpiperidin-1-yl]-3-(R a)-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one.

[0278] The compound of Example 4 is 6-(4-amino-4-ethylpiperidin-1-yl)-3-(S a )-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one and 6-(4-amino-4-ethylpiperidin-1-yl)-3-(R a )-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one.

[0279] The compound of Example 5 is 6-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(S a )-(2,3-difluorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one and 6-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(R a )-(2,3-difluorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one.

[0280] The compound of Example 6 is 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(4-bromo-2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one and 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(4-bromo-2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one.

[0281] The compound of Example 8 is 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a)-(2-bromo-3-chlorophenyl)-2-methylpyrimidin-4(3H)-one and 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2-bromo-3-chlorophenyl)-2-methylpyrimidin-4(3H)-one.

[0282] Example 9 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-chloro-3-(R a )-(2,3-Dichlorophenyl)-2-methylpyrimidin-4(3H)-one [ka] 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a To a solution of 2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one (Example 2b, 2.5 g, 5.9 mmol) was added NCS (946 mg, 7.09 mmol) and the resulting mixture was stirred at room temperature for 10 min. The mixture was concentrated under reduced pressure. The residue was purified by silica gel chromatography (2-15% MeOH in DCM with 2% NH4OH) to give the title compound as a white solid (2.1 g, 78% yield). MS (ES + ) C 20 H 23 Cl3N4O2 Calculated: 456, Found: 457 [M+ H] + . 1H NMR (600 MHz, DMSO-d6) δ 7.83 (dd, J = 8.1, 1.6 Hz, 1H), 7.62 (dd, J = 8.0, 1.6 Hz, 1H), 7.57 (t, J = 8.0 Hz, 1H), 4.09 - 4.01 (m, 1H), 3.96 - 3.87 (m, 2H), 3.67 (d, J = 8.4 Hz, 1H), 3.53 - 3.46 (m, 2H), 3.40 (ddd, J = 12.9, 9.3, 3.1 Hz, 1H), 2.91 (d, J = 5.1 Hz, 1H), 2.00 (s, 3H), 1.81 (ddd, J = 13.2, 9.3, 3.6 Hz, 1H), 1.71 - 1.65 (m, 1H), 1.59 - 1.54 (m, 1H), 1.54 - 1.48 (m, 1H), 1.08 (d, J = 6.4 Hz, 3H).

[0283] Examples 10a and 10b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2,3-Dichlorophenyl)-2,5-dimethylpyrimidin-4(3H)-one (Example 10a): [ka] 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2,3-Dichlorophenyl)-2,5-dimethylpyrimidin-4(3H)-one (Example 10b): [ka] Method A Step 1: 3-(2,3-dichlorophenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one [ka] To a suspension of N-(2,3-dichlorophenyl)acetimidamide hydrochloride (Example 1, Step 1) (44 g, 184 mmol) in EtOH (184 mL) was added diethyl 2-methylmalonate (62.6 ml, 367 mmol) and EtONa (206 ml, 551 mmol), and the resulting mixture was stirred in a sealed tube at 120° C. for 18 h. The reaction mixture was allowed to cool to room temperature and the volatiles were removed under reduced pressure. Water (200 mL) was added, the mixture was cooled to 0° C., and HCl (6 M) was added to adjust the pH to 2. The reaction was allowed to warm to room temperature and stirred for 1 h. The reaction mixture was filtered through glass fiber paper, the solid was washed with Et2O, collected, and dried under reduced pressure to give the title compound as a pale yellow solid (44.6 g, 156 mmol, 85% yield). MS (ES + ) C 12 H 10 Cl2N2O2 Calculated: 284, Found: 285 [M+H] + .

[0284] The compound in step 1 is 3-(S a )-(2,3-dichlorophenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one and 3-(R a )-(2,3-dichlorophenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one.

[0285] Step 2: 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2,3-dichlorophenyl)-2,5-dimethylpyrimidin-4(3H)-one (Example 10a) and 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2,3-Dichlorophenyl)-2,5-dimethylpyrimidin-4(3H)-one (Example 10b) To a suspension of 3-(2,3-dichlorophenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one (30 g, 105 mmol) and (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine dihydrochloride (28.1 g, 116 mmol) in acetonitrile (351 mL) was added DBU (50.8 mL, 337 mmol) and BOP (51.2 g, 116 mmol), and the resulting mixture was stirred at room temperature for 24 hours. (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine dihydrochloride (12.8 g, 52.5 mmol) and DBU (15.8 mL, 105 mmol) were added, and the mixture was stirred at room temperature for another 24 hours. The reaction mixture was concentrated under reduced pressure. The residue was partitioned between DCM (200 mL) and water (200 mL), the layers were separated, and the aqueous layer was extracted with DCM (3×200 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (2-15% MeOH in DCM with 2% NH4OH) to give the title compound as a mixture of diastereomers as an off-white solid. This mixture of diastereomers was separated by chiral SFC (mobile phase: CO2 / methanol (0.25% isopropylamine) = 60 / 40; flow rate: 80 g / min; 5 min; column temperature: 25 °C; back pressure: 100 bar; column: Chiral Technologies Chiralpak AD-H, 2.1 x 25.0 cm) to give the title compounds Example 10a (19.51 g, 42%, 98% ee) as a white solid (single diastereomer) and Example 10b (19.25 g, 42%, >99% ee) as a white solid (single diastereomer).

[0286] Example 10a 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2,3-Dichlorophenyl)-2,5-dimethylpyrimidin-4(3H)-one: MS (ES + ) C21 H 26 Cl2N4O2 Calculated: 436, Found: 437 [M+ H] + . 1 H NMR (600 MHz, DMSO-d6) δ 7.83 - 7.77 (m, 1H), 7.57 - 7.50 (m, 2H), 4.09 - 4.02 (m, 1H), 3.66 (d, J = 8.4 Hz, 1H), 3.58 - 3.51 (m, 2H), 3.49 (d, J = 8.4 Hz, 1H), 3.21 (ddd, J = 12.9, 9.3, 3.2 Hz, 1H), 3.13 (ddd, J = 12.9, 9.4, 3.0 Hz, 1H), 2.89 (d, J = 5.1 Hz, 1H), 1.97 (s, 3H), 1.89 (s, 3H), 1.78 (ddd, J = 13.3, 9.5, 3.6 Hz, 1H), 1.66 (ddd, J = 13.1, 9.1, 3.7 Hz, 1H), 1.57 - 1.52 (m, 1H), 1.52 - 1.47 (m, 1H), 1.08 (d, J = 6.4Hz, 3H).

[0287] Example 10b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2,3-Dichlorophenyl)-2,5-dimethylpyrimidin-4(3H)-one: MS (ES + ) C 21 H 26 Cl2N4O2 Calculated: 436, Found: 437 [M+ H] + . 1H NMR (600 MHz, DMSO-d6) δ 7.83 - 7.77 (t, J = 4.8 Hz, 1H), 7.57 - 7.50 (d, J = 4.8 Hz, 2H), 4.09 - 4.02 (m, 1H), 3.65 (d, J = 8.4 Hz, 1H), 3.58 - 3.51 (m, 2H), 3.49 (d, J = 8.4 Hz, 1H), 3.22 (ddd, J = 13, 9.5, 2.5 Hz, 1H), 3.12 (ddd, J = 13.0, 9.5, 2.5 Hz, 1H), 2.89 (d, J = 5.1 Hz, 1H), 1.97 (s, 3H), 1.89 (s, 3H), 1.78 (ddd, J = 13.2, 9.5, 3.7 Hz, 1H), 1.66 (ddd, J = 13.2, 9.5, 3.7 Hz, 1H), 1.58 - 1.46 (m, 2H), 1.28 (bs, 2H), 1.08 (d, J = 6.4 Hz, 3H).

[0288] Method B Process 1:1-(R a )-(2,3-Dichlorophenyl)-2,5-dimethyl-6-oxo-1,6-dihydropyrimidin-4-yl trifluoromethanesulfonate [ka] 3-(S) in DCM (1.00 L) a )-(2,3-dichlorophenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one and 3-(R aTo a mixture of 2,3-dichlorophenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one (Example 10, Method A, Step 1) (100 g, 351 mmol) and DIPEA (183 mL, 1.05 mol) was added TfO (116 mL g, 701 mmol, 116 mL) dropwise at -25 °C. The resulting mixture was stirred at -25 °C to -20 °C for 1 h and at 20 °C for 18 h. Two batches of the reaction mixture were mixed. Water (1 L) was added to the reaction mixture and the resulting mixture was extracted with CHCl (1 L x 2). The combined organic layers were washed with 1 M HCl (1 L, aq), dried over NaSO, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (EtOAc in PE, 20%) to give a mixture of diastereomers as a brown solid (144 g, 336 mmol, 47.8% yield). The mixture of diastereomers was separated by SFC (column: Daicel CHIRALPAK AD (250 mm x 50 mm, 10 um); mobile phase: [Neu-IPA]; B%: 15%-15%, 2.9 min, 1100 min) to give the title compound as a brown solid (56.4 g, 18%, ee=99.5%). MS (ES + ) C 13 H9Cl2F3N2O4S Calculated: 416, Found: 417 [M+H] + .

[0289] Step 2: 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2,3-Dichlorophenyl)-2,5-dimethylpyrimidin-4(3H)-one (Example 10b) A solution of (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine (23.3 g, 95.6 mmol, 1.05 equiv, 2HCl) in DMF (50.0 mL) was diluted with DIPEA (47.1 g, 364 mmol, 63.5 mL) and 1-(R aA solution of (3S,4S)-(2,3-dichlorophenyl)-2,5-dimethyl-6-oxo-1,6-dihydropyrimidin-4-yl trifluoromethanesulfonate (38.0 g, 91.1 mmol, 1.00 equiv) was added at 0° C. The resulting mixture was stirred at 15° C. for 18 h, and (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (1.11 g, 4.55 mmol, 2HCl) was added. The resulting mixture was stirred at 25° C. for 15 h. The reaction mixture was concentrated under reduced pressure. K2CO3 (15%, 500 mL, aq.) was added, and the aqueous phase was extracted with DCM (200 mL×3). The combined organic layers were washed with brine (400 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, MeOH in DCM, 5-20%) followed by reverse-phase column chromatography (0.1% NH3·H2O, MeCN:H2O (65:35)). The residue was dissolved in hot MeOH (250 mL) and activated charcoal (2.70 g) was added to the resulting solution and the mixture was stirred at 60 °C for 15 min. The mixture was filtered and concentrated under reduced pressure to give the title compound Example 10b (26.5 g, 66.5%) as an off-white solid.

[0290] Example 11 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2,3-Dichlorophenyl)-2-methyl-5-(trifluoromethyl)pyrimidin-4(3H)-one TFA salt [ka] 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-chloro-3-(R aA suspension of )-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one (Example 9) (35 mg, 0.083 mmol), TFA (9.6 μL, 0.12 mmol), and bis(((trifluoromethyl)sulfinyl)oxy)zinc (55 mg, 0.16 mmol) was sonicated to give a homogeneous suspension, which was then cooled to °C and tert-butyl hydroperoxide (34 μL, 0.25 mmol) was added dropwise. The resulting mixture was allowed to warm to room temperature and stirred for 2 h. Water (1 mL) was added, the layers were separated, and the aqueous layer was extracted with DCM (1 mL x 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by mass-sensitive preparative HPLC (mobile phase: A = 0.1% TFA / HO, B = 0.1% TFA / MeCN; gradient: B = 20-50%; 20 min; column: XBridge C18, 5 μm, 19 mm × 150 mm) to give the title compound as a white solid (single diastereomer) (15 mg, 30% yield). MS (ES) + ) C 21 H 23 Cl2F3N4O2 Calculated: 490, Found: 491 [M+ H] + . 1 H NMR (600 MHz, DMSO-d6) δ 7.90 (s, 3H), 7.84 (dd, J = 7.9, 1.8 Hz, 1H), 7.63 - 7.56 (m, 2H), 4.24 - 4.17 (m, 1H), 3.96 (d, J = 14.0 Hz, 1H), 3.91 - 3.83 (m, 2H), 3.72 (d, J = 9.0 Hz, 1H), 3.50 - 3.44 (m, overlap H2O, 1H), 3.32 - 3.16 (m, overlap H2O, 2H), 2.03 (s, 3H), 1.78 (d, J = 13.8 Hz, 3H), 1.61 (d, J = 13.2 Hz, 1H), 1.21 (d, J = 6.5 Hz, 3H).

[0291] Examples 12a and 12b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-bromo-3-(S a )-(2,3-Dichlorophenyl)-2-methylpyrimidin-4(3H)-one (Example 12a): [ka] 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-bromo-3-(R a )-(2,3-Dichlorophenyl)-2-methylpyrimidin-4(3H)-one (Example 12b): [ka] Step 1: 5-Bromo-(2,3-dichlorophenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one [ka] To a solution of 3-(2,3-dichlorophenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one (Example 1, step 2) (540 mg, 2 mmol) in DCM (8 mL) was added a solution of NBS (356 mg, 2 mmol) in DCM (2 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was filtered to give the title compound as a white solid (680 mg, 97.1%). MS (ES + ) C 11 H7BrCl2N2O2 Calculated value: 350, Found value: 351 [M+H] + .

[0292] The compound in step 1 is 5-bromo-(S a )-(2,3-dichlorophenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one and 5-bromo-(R a )-(2,3-dichlorophenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one.

[0293] Step 2: 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-bromo-3-(R a )-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3H)-one (Example 12a) and 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-bromo-3-(S a )-(2,3-Dichlorophenyl)-2-methylpyrimidin-4(3H)-one (Example 12b) 5-Bromo-3-(2,3-dichlorophenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one (80 mg, 0.23 mmol), (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine (67 mg, 0.27 mmol), BOP (121 mg, 0.27 mmol), and DBU (174 mg, 1.14 mmol) in MeCN (2 mL) were stirred at room temperature for 2 h. The mixture was concentrated and purified by preparative HPLC (NH4HCO3) to give a solid. This mixture of diastereomers was separated by chiral SFC (mobile phase: CO2 / methanol (0.2% MEA) = 30 / 70; flow rate: 80 g / min; 5 min; column temperature: 35°C; back pressure: 100 bar; column: AD 20 x 250 mm, 10 um (Daicel)) to give Example 12a as a white solid (18 mg, 16%) and Example 12b as a white solid (15 mg, 13%).

[0294] Example 12a 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-bromo-3-(S a )-(2,3-Dichlorophenyl)-2-methylpyrimidin-4(3H)-one: MS (ES + ) C 20 H 23 BrCl2N4O2 Calculated: 500, 502, Found: 501, 503 [M+ H] +. 1H NMR (500 MHz, DMSO) δ 7.83 (dd, J = 8.1, 1.5 Hz, 1H), 7.62 (dd, J = 8.0, 1.5 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 4.09 - 4.02 (m, 1H), 3.93 - 3.82 (m, 2H), 3.66 (d, J = 8.5 Hz, 1H), 3.50 - 3.36 (m, 3H), 2.91 (d, J = 5.1 Hz, 1H), 2.00 (s, 3H), 1.86 - 1.78 (m, 1H), 1.68 - 1.59 (m, 1H), 1.61 - 1.47 (m, 2H), 1.08 (d, J = 6.4 Hz, 3H).

[0295] Example 12b 6-((3S,4S)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル)-5-ブロモ-3-(R a )-(2,3-ジクロロフェニル)-2-メチルピリジン-4(3H)-オン:MS (ES + ) C 20 H 23 BrCl2N4O2 calculated value: 500, 502, measured value: 501, 503 [M+ H] + . 1H NMR (500 MHz, DMSO) δ 7.83 (dd, J = 8.0, 1.6 Hz, 1H), 7.62 (dd, J = 7.9, 1.5 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 4.10 - 4.00 (m, 1H), 3.94 - 3.82 (m, 2H), 3.66 (d, J = 8.4 Hz, 1H), 3.53 - 3.36 (m, 3H), 2.91 (d, J = 5.0 Hz, 1H), 2.00 (s, 3H), 1.81 (ddd, J = 13.0, 9.3, 3.4 Hz, 1H), 1.69 (ddd, J = 12.9, 9.1, 3.6 Hz, 1H), 1.61 - 1.46 (m, 2H), 1.08 (d, J = 6.4 Hz, 3H).

[0296] Examples 13a and 13b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2-Chloro-3-methylphenyl)-2-methylpyrimidin-4(3H)-one TFA salt (Example 13a): [ka] 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2-Chloro-3-methylphenyl)-2-methylpyrimidin-4(3H)-one TFA salt (Example 13b): [ka] Step 1: tert-Butyl 2-chloro-3-methylphenylcarbamate [ka] A mixture of 1-bromo-2-chloro-3-methylbenzene (4.0 g, 19.6 mmol), Pd2dba3 (1014 mg, 0.98 mmol), Xantphos (566 mg, 0.98 mmol), tert-butyl carbamate (3.41 g, 29.4 mmol), and Cs2CO3 (9.58 g, 29.4 mmol) in dioxane (120 mL) was stirred at 110 °C for 2 h and then cooled to room temperature. Water (150 mL) was added and the mixture was extracted with EtOAc (150 mL x 2). The organic layer was dried and concentrated. The residue was purified by flash column chromatography (PE, 100%) to give the title compound (4.2 g, 89%). MS (ES) + ) C 12 H 16 ClNO2 calculated value: 241, found value: 187 [M-55+H] + .

[0297] Step 2: 2-Chloro-3-methylaniline [ka] A mixture of tert-butyl 2-chloro-3-methylphenylcarbamate (4.2 g, 17.4 mmol) in 2M HCl (40 mL in MeOH) was stirred at room temperature for 1 h. The mixture was concentrated, washed with EtO (40 mL), and dried under vacuum to give the title compound as a yellow solid (2.3 g, 93%). MS (ES + ) C7H8ClN Calculated: 141, Found: 142 [M+H] + .

[0298] Step 3: N-(2-chloro-3-methylphenyl)acetimidamide [ka] A mixture of 2-chloro-3-methylaniline (1.4 g, 9.93 mmol) in HCl (1N in CH3CN, 15 ml) was heated at 120° C. for 4 h. The reaction mixture was cooled to room temperature, filtered, and the filter cake was washed with Et2O (15 mL). The filter cake was dried under vacuum to give the title compound (1.2 g, 66%). MS (ES + ) C9H 11 ClN2 calculated value: 182, found value: 183 [M+H] + .

[0299] Step 4: 3-(2-chloro-3-methylphenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one [ka] To a solution of N-(2-chloro-3-methylphenyl)acetimidamide (1.2 g, 6.6 mmol) in 2-methoxyethan-1-ol (12 mL) was added diethyl malonate (4.22 g, 26.36 mmol) and CH3ONa / CH3OH (4 M, 6.6 mL, 26 mmol). The mixture was heated at 120° C. for 16 h. The mixture was cooled to room temperature, poured into water (50 mL), and the aqueous phase was washed with Et2O (50 mL). The aqueous layer was acidified to about pH 2 with 6N HCl and extracted with EtOAc (50 mL x 3). The organic layer was dried and concentrated. The residue was washed with EtOAc to give the title compound as a white solid (300 mg, 18%). MS (ES + ) C 12 H 11 ClN2O2 Calculated: 250, Found: 251 [M+H] + .

[0300] The compound in step 4 is 3-(S a )(2-chloro-3-methylphenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one and 3-(R a )(2-chloro-3-methylphenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one.

[0301] Step 5: 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2-chloro-3-methylphenyl)-2-methylpyrimidin-4(3H)-one TFA salt (Example 13a) and 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2-Chloro-3-methylphenyl)-2-methylpyrimidin-4(3H)-one TFA salt (Example 13b) To a suspension of 3-(2-chloro-3-methylphenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one (150 mg, 0.6 mmol) and (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine dihydrochloride (173 mg, 0.72 mmol) in MeCN (3 ml) was added DBU (183 mg, 1.2 mmol) and BOP (318 mg, 0.72 mmol), and the resulting mixture was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC (A: water (0.05% TFA), B: ACN) with 18-28% B in 10 min, stopped at 15 min. Column: Sunfire prep C18 10 μm, OBD 19×250 mm) to give the title compound Example 13a as a TFA salt (40 mg, 25%) and the title compound Example 13b as a TFA salt (60 mg, 38%).

[0302] Example 13a 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2-Chloro-3-methylphenyl)-2-methylpyrimidin-4(3H)-one TFA salt: MS (ES + ) C 23 H 28 ClF3N4O4 Calculated: 402, Found: 403 [M+ H] + . 1H NMR (500 MHz, DMSO) δ 7.92 (s, 3H), 7.49-7.48 (m, 1H), 7.41-7.38 (m, 1H), 7.29-7.28 (m, 1H), 5.43 (s, 1H), 4.21-4.19 (m, 2H), 3.87-3.85 (m, 1H), 3.70-3.68(m, 1H), 3.41 - 3.39 (m, 2H), 3.05 - 3.02 (m, 2H), 2.41 (s, 3H), 1.96 (s, 3H), 1.69-1.68 (m, 3H), 1.55-1.53 ​​(m, 1H), 1.21-1.20 (d, J= 7 Hz, 3H).

[0303] Example 13b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2-Chloro-3-methylphenyl)-2-methylpyrimidin-4(3H)-one TFA salt: MS (ES + ) C 23 H 28 ClF3N4O4 Calculated: 402, Found: 403 [M+ H] + . 1H NMR (500 MHz, DMSO) δ 8.01(s, 3H), 7.49-7.47 (m, 1H), 7.41-7.38 (m, 1H), 7.29-7.28 (m, 1H), 5.43 (s, 1H), 4.22-4.19 (m, 2H), 3.88-3.86 (m, 2H), 3.69 - 3.68 (m, 1H), 3.42 - 3.40 (m, 1H), 3.06 - 3.00 (m, 2H), 2.41 (s, 3H), 1.96 (s, 3H), 1.71-1.68 (m, 3H), 1.54-1.51 (m, 1H), 1.22-1.21 (d, J= 6 Hz, 3H).

[0304] Examples 14a and 14b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2-Chloro-3-(trifluoromethyl)phenyl)-2-methylpyrimidin-4(3H)-one TFA salt (Example 14a): [ka] 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2-Chloro-3-(trifluoromethyl)phenyl)-2-methylpyrimidin-4(3H)-one TFA salt (Example 14b): [ka] Examples 14a and 14b were synthesized using methods similar to those used for Examples 13a and 13b. In general, these examples can be prepared by the methods disclosed herein. These examples can be prepared as the free base or as a TFA salt.

[0305] Example 14a 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2-Chloro-3-(trifluoromethyl)phenyl)-2-methylpyrimidin-4(3H)-one TFA salt: MS (ES + ) C 21 H 24 ClF3N4O2 Calculated: 456, Found: 457 [M+H] + .

[0306] Example 14b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2-Chloro-3-(trifluoromethyl)phenyl)-2-methylpyrimidin-4(3H)-one TFA salt: MS (ES + ) C 21 H 24 ClF3N4O2 Calculated: 456, Found: 457 [M+H] + .

[0307] Examples 15a and 15b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2,3-Dichloro-4-phenoxyphenyl)-2-methylpyrimidin-4(3H)-one (Example 15a): [ka] 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a)-(2,3-Dichloro-4-phenoxyphenyl)-2-methylpyrimidin-4(3H)-one (Example 15b): [ka] Step 1: 2,3-Dichloro-1-nitro-4-phenoxybenzene [ka] To a solution of phenol (1.1 g, 12 mmol) in dry N,N-dimethylformamide (15 mL) was added NaH (520 mg, 13 mmol, 60%) in portions at 0° C., and the resulting mixture was stirred at 0° C. for 10 min. 2,3-Dichloro-1-fluoro-4-nitrobenzene (2.1 g, 10 mmol) was added, and the mixture was allowed to warm to room temperature and stirred overnight. The mixture was purified by silica gel chromatography (EtOAc in PE, 0-15%) to give the title compound as a yellow solid (2.0 g, 67%). MS (ES + ) C 12 H7Cl2NO3 calculated: 282, found: 283.

[0308] Step 2: 2,3-Dichloro-4-phenoxyaniline [ka] 2,3-Dichloro-1-nitro-4-phenoxybenzene (1.8 g, 6.4 mmol) and SnCl2.2H2O (14.3 g, 64 mmol) in EtOH (20 mL) were stirred at 85 °C for 5 h. The resulting mixture was adjusted to pH > 9 with saturated aqueous NaHCO3, filtered, and washed with EtOAc (50 mL x 3). The organic phase was dried, concentrated under reduced pressure, and purified by silica gel chromatography (EtOAc in PE, 0-40%) to give the title compound as a tan solid (1.2 g, 73%). MS (ES + ) C 12 H9Cl2NO calculated: 252, found: 253.

[0309] Step 3: N-(2,3-dichloro-4-phenoxyphenyl)acetimidamide [ka] 2,3-Dichloro-4-phenoxyaniline (1.0 g, 3.9 mmol) in HCl / MeCN (1M, 20 mL) was heated in a sealed tube at 120° C. overnight. The mixture was cooled to room temperature, the solid was filtered, and washed with MeCN (5 mL) to give the title compound as a white solid (0.9 g, 70%). MS (ES + ) C 14 H 12 Cl2N2 calculated: 293, found: 294.

[0310] Step 4: 3-(2,3-dichloro-4-phenoxyphenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one [ka] The reaction was carried out as described for Method B in Step 2 of Example 1 to give the title compound as a tan solid (0.5 g, 54%). MS (ES + ) C 17 H 12 Cl2N2O3 calculated: 361, found: 362.

[0311] The compound in step 4 is 3-(S a )-(2,3-dichloro-4-phenoxyphenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one and 3-(R a )-(2,3-dichloro-4-phenoxyphenyl)-6-hydroxy-2-methylpyrimidin-4(3H)-one.

[0312] Step 5: 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a)-(2,3-dichloro-4-phenoxyphenyl)-2-methylpyrimidin-4(3H)-one (Example 15a) and 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2,3-Dichloro-4-phenoxyphenyl)-2-methylpyrimidin-4(3H)-one (Example 15b) The reaction was carried out as described for step 1 of Example 2. The mixture of diastereomers was separated by chiral SFC chiral HPLC (co-solvent: MeOH (0.2% methanol-ammonia), column: AD-H, 4.6×100 mm) to give the title compounds Example 15a (25 mg, 18%) and Example 15b (27 mg, 19%).

[0313] Example 15a 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2,3-Dichloro-4-phenoxyphenyl)-2-methylpyrimidin-4(3H)-one: MS (ES + ) C 26 H 28 Cl2N4O3 Calculated: 514, Found: 515 [M+ H] + . 1 H NMR (400 MHz, MeOD) δ 7.44 (m, 2H), 7.37 (dd, J = 9, 2 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 7.12 (dd, J = 9, 1 Hz, 1H), 7.07 (dd, J = 9, 2 Hz, 1H), 5.51 (s, 1H), 4.25 (m, 1H), 4.07 (m, 2H), 3.88 (d, J = 9 Hz, 1H), 3.74 (m, 1H), 3.73 (d, J = 9 Hz, 1H), 3.42 (m, 1H), 3.03 (d, J = 5 Hz, 1H), 2.13 (s, 3H), 1.83-1.67 (m, 4H), 1.23 (d, J = 6 Hz, 3H).

[0314] Example 15b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2,3-Dichloro-4-phenoxyphenyl)-2-methylpyrimidin-4(3H)-one: MS (ES + ) C 26 H 28 Cl2N4O3 Calculated: 514, Found: 515 [M+ H] + . 1H NMR (500 MHz, MeOD) δ 7.51 - 7.41 (m, 2H), 7.36 (dd, J = 8.8, 2.7 Hz, 1H), 7.24 (t, J = 7.4 Hz, 1H), 7.12 (dd, J = 8.6, 0.8 Hz, 2H), 7.07 (dd, J = 8.8, 1.8 Hz, 1H), 5.51 (d, J = 7.5 Hz, 1H), 4.30 - 4.21 (m, 1H), 4.07 (d, J = 4.8 Hz, 1H,) 4.07 (m, 1H), 3.89 (d, J = 8.7 Hz, 1H), 3.74 (d, J = 8.7 Hz, 1H), 3.42 (t, J = 10.0 Hz, 1H), 3.03 (d, J = 5.0 Hz, 1H), 2.14 (d, J = 3.9 Hz, 3H), 1.89 - 1.61 (m, 4H), 1.23 (dd, J = 11.7, 6.4 Hz, 3H).

[0315] Examples 16a and 16b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2,3-Dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-2-methylpyrimidin-4(3H)-one TFA salt (Example 16a): [ka] 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a)-(2,3-Dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-2-methylpyrimidin-4(3H)-one TFA salt (Example 16b): [ka] Examples 16a and 16b were synthesized using methods similar to those used for Examples 15a and 15b. In general, these examples can be prepared by the methods disclosed herein. These examples can be prepared as the free base or as a TFA salt.

[0316] Example 16a 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-2-methylpyrimidin-4(3H)-one TFA salt: MS (ES + ) C 24 H 28 Cl2N6O3 Calculated: 518, Found: 519 [M+H] + .

[0317] Example 16b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-2-methylpyrimidin-4(3H)-one TFA salt: MS (ES + ) C 24 H 28 Cl2N6O3 Calculated: 518, Found: 519 [M+H] + .

[0318] Example 17 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-chloro-3-(2,3-dichloropyridin-4-yl)-2-methylpyrimidin-4(3H)-one [ka] Step 1: N-(2,3-dichloropyridin-4-yl)acetimidamide [ka] To a solution of 2,3-dichloro-4-iodopyridine (1 g mg, 3.6 mmol) in DMF (5 ml) was added acetimidamide hydrochloride (345 mg, 3.65 mmol), Cs2CO3 (2.4 g, 7.4 mmol), and Cu(I)I (70 mg, 0.36 mmol), and the resulting mixture was stirred at 90° C. for 12 h. The reaction mixture was diluted with MeCN (20 ml), filtered through Celite, and the filtrate was concentrated under reduced pressure to give the title compound as a grey solid (0.83 g, 100%).

[0319] Step 2: 3-(2,3-dichloropyridin-4-yl)-6-hydroxy-2-methylpyrimidin-4(3H)-one [ka] To a suspension of N-(2,3-dichloropyridin-4-yl)acetimidamide (1) (500 mg, 2.45 mmol) in THF (5 ml) was added bis(2,4,6-trichlorophenyl)malonate (1.2 g mg, 2.6 mmol) and the resulting mixture was stirred at 90° C. for 2 h. The volatiles were removed under reduced pressure. The reaction mixture was diluted with EtOAc (20 mL) and washed with water (5 mL). The layers were separated and the organic layer was washed with brine (5 mL), dried over MgSO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel chromatography (0-20% MeOH in DCM) to give the title compound as a light orange solid (280 mg, 42% yield). MS (ES + ) C 10 H7Cl2N3O2 Calculated: 271, Found: 272 [M+H] + .

[0320] The compound in step 2 is 3-(R a )-(2,3-dichloropyridin-4-yl)-6-hydroxy-2-methylpyrimidin-4(3H)-one and 3-(S a )-(2,3-dichloropyridin-4-yl)-6-hydroxy-2-methylpyrimidin-4(3H)-one.

[0321] Step 3: 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichloropyridin-4-yl)-2-methylpyrimidin-4(3H)-one [ka] To 3-(2,3-dichloropyridin-4-yl)-6-hydroxy-2-methylpyrimidin-4(3H)-one (100 mg, 0.37 mol), (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decane-4-amine dihydrochloride (89 mg, 0.37 mmol), BOP (244 mg, 0.551 mmol) in DMF (2 ml) was added DBU (0.11 ml, 0.73 mmol), and the resulting mixture was stirred at room temperature for 1 h. The residue was purified by mass-sensitive preparative HPLC (mobile phase: A=0.1% TFA / HO, B=0.1% TFA / MeCN; gradient: B=10-50%; 20 min; column: C18) to give the title compound as a white solid (92 mg, 0.22 mmol, 59% yield). MS (ES + ) C 19 H 23 Cl2N5O2 Calculated: 423, Found: 424 [M+H] + .

[0322] The compound in step 3 is 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a)-(2,3-Dichloropyridin-4-yl)-2-methylpyrimidin-4(3H)-one and 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2,3-dichloropyridin-4-yl)-2-methylpyrimidin-4(3H)-one.

[0323] Step 4: 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-chloro-3-(2,3-dichloropyridin-4-yl)-2-methylpyrimidin-4(3H)-one A vial was charged with 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichloropyridin-4-yl)-2-methylpyrimidin-4(3H)-one (40 mg, 0.047 mmol), NCS (15 mg, 0.11 mmol), and DCM (1.0 ml). The mixture was stirred at room temperature for 5 min. The volatiles were removed under reduced pressure. The residue was purified by mass-directed preparative HPLC (mobile phase: A=0.1% TFA / H2O, B=0.1% TFA / MeCN; gradient: B=10-40%; 20 min; column: C18) to give the title compound as a white powder (12 mg, 0.026 mmol, 11% yield). MS (ES + ) C 19 H 22 Cl3N5O2 Calculated: 457, Found: 458 [M+H] + ; 1H NMR (500 MHz, DMSO-d6) δ 8.64 (d, J = 5.0 Hz, 1 H); 7.94 (m, 2 H); 7.82 (m. 1H); 4.16 - 4.26 (m, 2 H); 3.86 (m, 1 H); 3.71 (d, J = 10 Hz,1 H); 3.17 - 3.26 (m, 3 H); 2.81 (d, J =10.68 Hz, 1 H), 2.06 (s, 3H), 1.73 - 1.81 (m, 3 H), 1.62 (m, 1 H), 1.22 (d, J = 5.0 Hz, 3 H).

[0324] The compound of Example 17 is 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-chloro-3-(S a )-(2,3-dichloropyridin-4-yl)-2-methylpyrimidin-4(3H)-one and 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-chloro-3-(R a )-(2,3-dichloropyridin-4-yl)-2-methylpyrimidin-4(3H)-one.

[0325] Examples 18a and 18b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-2,5-dimethylpyrimidin-4(3H)-one (Example 18a): [ka] 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-2,5-dimethylpyrimidin-4(3H)-one (Example 18b): [ka] Step 1: 3-(2,3-dichloro-4-nitrophenoxy)-1-methyl-1H-pyrazole [ka] A mixture of 2,3-dichloro-1-fluoro-4-nitrobenzene (1.3 g, 6.2 mmol), 1-methyl-1,2-dihydro-3H-pyrazol-3-one (729 mg, 7.4 mmol), K2CO3 (1.7 g, 12.4 mmol) in MeCN (30 mL) was stirred at room temperature for 3 h. The reaction mixture was poured into water (50 mL) and extracted with EtOAc (100 mL x 3). The combined organic phase was dried (Na2SO4), filtered, and concentrated, and the residue was purified by silica gel chromatography (EtOAc in PE, 10%) to give the title compound as a white solid (1.5 g, 84%). MS (ES + ) C 10 H7Cl2N3O3 Calculated: 287, Found: 288 [M+H] + .

[0326] Step 2: 2,3-Dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)aniline [ka] To a solution of 3-(2,3-dichloro-4-nitrophenoxy)-1-methyl-1H-pyrazole (1.5 g, 5.2 mmol) in AcOH (10 mL) was added Fe (1.4 g, 26 mmol). The resulting mixture was stirred at 60° C. for 2 h. The reaction mixture was poured into ice-cold water (60 mL) and extracted with EtOAc (100 mL×3). The combined organic phase was dried (Na2SO4), filtered, and concentrated. The residue was purified by silica gel chromatography (EtOAc in PE, 50%) to give the title compound as a yellow solid (1.2 g, 90%). MS (ES + ) C 10H9Cl2N3O Calculated: 257, Found: 258 [M+H] + .

[0327] Step 3: N-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)acetimidamide [ka] A mixture of 2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)aniline (1.2 g, 4.7 mmol) in HCl / CH3CN (1M, 10 mL) was stirred in a sealed tube at 120° C. for 24 h. The mixture was concentrated and the residue was washed with Et2O (10 mL). The precipitate was filtered to give the title compound as a white solid (1.2 g, 86%). MS (ES + ) C 12 H 12 Cl2N4O Calculated: 298, Found: 299 [M+H] + .

[0328] Step 4: 3-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one [ka] To a solution of diethyl 2-methylmalonate (1.4 g, 8.0 mmol) in EtOH (6 mL) was added CH3ONa / CH3OH (4 M, 2 mL). The mixture was stirred at room temperature for 10 min. N-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)acetimidamide (600 mg, 2 mmol) was added and the mixture was stirred at 120 °C for 4 h. The mixture was poured into water (30 mL) and extracted with Et2O (2 x 30 mL). The pH of the aqueous layer was adjusted to pH 5 with AcOH and it was extracted with EtOAc (3 x 80 mL). The combined organic phase was dried (Na2SO4), filtered, and concentrated. The crude product was washed with Et2O (10 mL) to give the title compound as a white solid (320 mg, 42%). MS (ES + ) C 16 H 14 Cl2N4O3 Calculated: 380, Found: 381 [M+H] + .

[0329] The compound in step 4 is 3-(S a )-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one and 3-(R a )-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one.

[0330] Step 5: 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-2,5-dimethylpyrimidin-4(3H)-one (Example 18a) and 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a)-(2,3-Dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-2,5-dimethylpyrimidin-4(3H)-one (Example 18b) To a suspension of 3-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one (100 mg, 0.26 mmol) and (3S,4S)-3-methyl-2-oxa-8-azaspiro[4.5]decan-4-amine dihydrochloride (126 mg, 0.52 mmol) in MeCN (8 ml) was added DBU (395 mg, 2.6 mmol) and BOP (230 mg, 0.52 mmol) and the resulting mixture was stirred at room temperature for 48 h. The mixture was concentrated under reduced pressure and the residue was purified by preparative HPLC (mobile phase: A=0.05% TFA / HO, B=MeCN; gradient: B=21-31%; 10 min; column: C18) using a Chiralpak OZ column (20×250 mm) with CO and 0.2% methanol-ammonia (45:55) as eluents and a flow rate of 80 g / min and UV detection (214 nm) to separate the diastereomers to give Example 18a (7 mg, 5%) and Example 18b (9 mg, 7%) as white solids.

[0331] Example 18a 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(S a )-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-2,5-dimethylpyrimidin-4(3H)-one: MS (ES + ) C 25 H 30 Cl2N6O3 Calculated: 532, Found: 533 [M+ H] + . 1H NMR (500 MHz, MeOD) δ 7.46 (d, J = 2.5 Hz, 1H), 7.14-7.23 (m, 2H), 5.84 (d, J = 2.5 Hz, 1H), 4.12-4.15 (m, 1H), 3.71-3.78 (m, 1H), 3.62-3.68 (m, 6H), 3.17-3.20 (m, 3H), 2.95-2.96 (m, 1H), 1.99 (s, 3 H), 1.90 (s, 3 H), 1.57-1.78 (m, 4H), 1.18 (s, 1 H), 1.12 (d, J = 6 Hz, 3H).

[0332] Example 18b 6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(R a )-(2,3-dichloro-4-((1-methyl-1H-pyrazol-3-yl)oxy)phenyl)-2,5-dimethylpyrimidin-4(3H)-one: MS (ES + ) C 25 H 30 Cl2N6O3 Calculated: 532, Found: 533 [M+ H] + . 1 H NMR (500 MHz, MeOD) δ 7.58 (d, J = 2.5 Hz, 1H), 7.26-7.36 (m, 2H), 5.96 (d, J = 3 Hz, 1H), 4.24-4.26 (m, 1H), 3.83-3.89 (m, 1H), 3.74-3.80 (m, 6H), 3.18-3.29 (m, 3H), 3.05-3.06 (m, 1H), 2.69 (s, 1H), 2.11 (s, 3H), 2.02 (s, 3H), 1.66-1.88 (m, 4H), 1.23 (d, J = 7 Hz, 3H).

[0333] Examples 19a and 19b 4-(4-(4-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-2,5-dimethyl-6-oxopyrimidin-1(6H)-yl)-(Sa )-(2,3-Dichlorophenoxy)-N-methylbenzamide (Example 19a): [ka] 4-(4-(4-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-2,5-dimethyl-6-oxopyrimidin-1(6H)-yl)-(R a )-(2,3-Dichlorophenoxy)-N-methylbenzamide (Example 19b): [ka] Examples 19a and 19b were synthesized using methods similar to those used for Examples 15a and 15b. In general, these examples can be prepared by the methods disclosed herein. These examples can be prepared as the free base or as a TFA salt.

[0334] Example 19a 4-(4-(4-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-2,5-dimethyl-6-oxopyrimidin-1(6H)-yl)-(S a )-(2,3-Dichlorophenoxy)-N-methylbenzamide: MS (ES + ) C 29 H 33 Cl2N5O4 Calculated: 585, Found: 586 [M+H] + .

[0335] Example 19b 4-(4-(4-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-2,5-dimethyl-6-oxopyrimidin-1(6H)-yl)-(R a )-(2,3-Dichlorophenoxy)-N-methylbenzamide: MS (ES + ) C 29 H 33 Cl2N5O4 Calculated: 585, Found: 586 [M+H] + .

[0336] Examples 20a and 20b 3-(4-((1H-pyrazol-3-yl)oxy)-(S a )-2,3-dichlorophenyl)-6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-2,5-dimethylpyrimidin-4(3H)-one (Example 20a): [ka] 3-(4-((1H-pyrazol-3-yl)oxy)-(R a )-2,3-dichlorophenyl)-6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-2,5-dimethylpyrimidin-4(3H)-one (Example 20b): [ka] Step 1: tert-Butyl 3-(2,3-dichloro-4-nitrophenoxy)-1H-pyrazole-1-carboxylate [ka] A mixture of tert-butyl 3-oxo-2,3-dihydro-1H-pyrazole-1-carboxylate (687 mg, 3.73 mmol), 2,3-dichloro-1-fluoro-4-nitrobenzene (650 mg, 3.11 mmol), and K2CO3 (858 mg, 6.22 mmol) in DMSO (10 mL) was stirred at room temperature for 4 h. Water (20 mL) was added and the mixture was extracted with EtOAc. The combined organic phase was dried over Na2SO4, filtered, and purified by column chromatography (EtOAc in PE, 20-50%) to give the title compound as a yellow solid (800 mg, 67%). MS (ES + ) C 14 H 13 Cl2N3O5 Calculated: 373, Found: 318 [M-56+H] + .

[0337] Step 2: tert-Butyl 3-(4-amino-2,3-dichlorophenoxy)-1H-pyrazole-1-carboxylate [ka] A suspension of tert-butyl 3-(2,3-dichloro-4-nitrophenoxy)-1H-pyrazole-1-carboxylate (1.2 g, 3.2 mmol), Pt / C (200 mg) in EtOH (100 mL) was stirred at room temperature under H2 atmosphere for 16 h. The mixture was filtered and the filtrate was concentrated to give the title compound as a beige solid (1.1 g, 100%). MS (ESI + ) C 14 H 15 Cl2N3O3 Calculated: 343, Found: 288 [M-56+H] + .

[0338] Step 3: N-(4-((1H-pyrazol-3-yl)oxy)-2,3-dichlorophenyl)acetimidamide [ka] A mixture of tert-butyl 3-(4-amino-2,3-dichlorophenoxy)-1H-pyrazole-1-carboxylate (1.1 g, 3.2 mmol) in HCl / CH3CN (1 M, 20 mL) was stirred in a sealed tube at 110° C. for 4 h. The mixture was concentrated to give N-(4-((1H-pyrazol-3-yl)oxy)-2,3-dichlorophenyl)acetimidamide as crude product. MS (ESI + ) C 11 H 10 Cl2N4O Calculated: 284, Found: 285 [M+H] + .

[0339] Step 4: 3-(4-((1H-pyrazol-3-yl)oxy)-2,3-dichlorophenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one [ka] To a mixture of N-(4-((1H-pyrazol-3-yl)oxy)-2,3-dichlorophenyl)acetimidamide (600 mg, 2.11 mmol), diethyl 2-methylmalonate (1.84 g, 10.6 mmol) in EtOH (10 mL) was added CH3ONa / CH3OH (4 M, 2.64 mL). The mixture was stirred at 110° C. for 5 h. The mixture was concentrated and dissolved in water (20 mL). The aqueous layer was extracted with EtOAc (20 mL) and the pH was adjusted to 5 with 6N HCl. A solid precipitated and was collected by filtration to give the title compound as a beige solid (300 mg, 38.7%). MS (ESI + ) C 15 H 12 Cl2N4O3 Calculated: 366, Found: 367 [M+H] + .

[0340] The compound in step 4 is 3-(4-((1H-pyrazol-3-yl)oxy)-(S a )-2,3-dichlorophenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one and 3-(4-((1H-pyrazol-3-yl)oxy)-(R a )-2,3-dichlorophenyl)-6-hydroxy-2,5-dimethylpyrimidin-4(3H)-one.

[0341] Step 5: 3-(4-((1H-pyrazol-3-yl)oxy)-(S a )-2,3-dichlorophenyl)-6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-2,5-dimethylpyrimidin-4(3H)-one (Example 20a) and 3-(4-((1H-pyrazol-3-yl)oxy)-(R a )-2,3-dichlorophenyl)-6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-2,5-dimethylpyrimidin-4(3H)-one (Example 20b) The experiment was carried out as described for step 5 of Examples 18a and 18b. The mixture was separated using a Chiralpak OZ column (20×250 mm) with CO and 0.2% methanol-ammonia (50:50) as eluents at a flow rate of 80 g / min and UV detection (214 nm) to give Example 20a (15 mg, 11%) and Example 20b (13 mg, 11%) as white solids.

[0342] Example 20a 3-(4-((1H-pyrazol-3-yl)oxy)-(S a )-2,3-dichlorophenyl)-6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-2,5-dimethylpyrimidin-4(3H)-one: MS (ES + ) C 24 H 28 Cl2N6O3 Calculated: 518, Found: 519 [M+ H] + . 1H NMR (500 MHz, DMSO) δ 12.57 (d, J = 0.4 Hz, 1H), 7.78 (s, 1H), 7.48 (d, J = 8.9 Hz, 1H), 7.18 (d, J = 8.9 Hz, 1H), 6.05 (s, 1H), 4.12 - 3.99 (m, 1H), 3.67 (d, J = 8.4 Hz, 1H), 3.60 - 3.52 (m, 2H), 3.50 (d, J = 8.4 Hz, 1H), 3.23 - 3.07 (m, 2H), 2.93 (d, J = 4.9 Hz, 1H), 2.00 (s, 3H), 1.89 (s, 3H), 1.81 - 1.74 (m, 1H), 1.70 - 1.63 (m, 1H), 1.59 - 1.47 (m, 2H), 1.23 (s, 1H), 1.09 (d, J = 6.3 Hz, 3H).

[0343] Example 20b 3-(4-((1H-pyrazol-3-yl)oxy)-(R a)-2,3-dichlorophenyl)-6-((3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-2,5-dimethylpyrimidin-4(3H)-one: MS (ES + ) C 24 H 28 Cl2N6O3 Calculated: 518, Found: 519 [M+ H] + . 1H NMR (500 MHz, DMSO) δ 12.57 (s, 1H), 7.81 - 7.75 (m, 1H), 7.48 (d, J = 8.9 Hz, 1H), 7.18 (d, J = 9.0 Hz, 1H), 6.05 (t, J = 2.1 Hz, 1H), 4.10 - 4.01 (m, 1H), 3.67 (d, J = 8.5 Hz, 1H), 3.61 - 3.51 (m, 2H), 3.50 (d, J = 8.5 Hz, 1H), 3.23 - 3.18 (m, 1H), 3.15 - 3.06 (m, 1H), 2.93 (d, J = 4.9 Hz, 1H), 2.00 (s, 3H), 1.89 (s, 3H), 1.80 - 1.75 (m, 1H), 1.70 - 1.63 (m, 1H), 1.58 - 1.48 (m, 2H), 1.32 - 1.19 (m, 2H), 1.09 (d, J = 6.4Hz, 3H).

[0344] Example 21: Biological activity assay The activity of the compounds in the examples disclosed herein as PTPN11 inhibitors is illustrated in the following assay.

[0345] PTPN11 enzyme assay Recombinant full-length wild-type human PTPN11 protein and recombinant full-length E76K mutant human PTPN11 protein were cloned, expressed (Escherichia coli system), and isolated by a two-step purification consisting of Ni affinity chromatography followed by S75 size-exclusion chromatography.

[0346] Phosphatase activity of full-length wild-type PTPN11 (PTPN11-WT) or PTPN11-E76K mutant enzyme was measured using fluorogenic 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP, Molecular Probes) as substrate. Enzyme (250 pM) was incubated with or without increasing compound concentrations in assay buffer (62.5 mM HEPES, 125 mM NaCl, 1 mM EDTA, 1.25 mM TECP, 0.1% BSA) for 30 min at room temperature. Reactions were initiated by adding room temperature DiFMUP (50 μM) into a 384-well black plate containing a final reaction volume of 20 uL assay buffer. After 1 h, the fluorescent signal of DiFMUP (excitation: 340 / emission: 460) was measured using an Envision plate reader. IC 50 Dose-response curves were analyzed using regression curve fitting (GeneData Screener). Curves were normalized to a positive control with no inhibitor and a negative control with no substrate. The results are presented in Table 2 below. [Table 2]

[0347] ERK phosphorylation (phospho-ERK) target engagement assay KYSE-520 cells (10,000 cells / well) were seeded in 20 uL of medium (RPMI-1640 without phenol red and containing 10% FBS) on 384-well plates and incubated at 37°C in 5% CO2 for 16 h. DMSO (control) or increasing concentrations of compounds were diluted in medium and added to the 384-well plates (10 uL / well, 1% final DMSO concentration), after which cells were incubated with compounds for 2 h. Phosphorylated ERK levels were measured using a TR-FRET-based phosphorylated ERK1 / 2 HTRF kit (CisBio, 64ERKPEH) according to the manufacturer's recommendations, and the fluorescent signal was measured at 665 nm and 620 nm using a Synergy Neo plate reader. Dose-response curves were analyzed using IC50 regression curve fitting (GeneData Screener). Curves were normalized to a positive control containing no inhibitor and a negative control containing 1 μM selumetinib. Some compounds of the invention have an IC of less than 1 μM. 50 showed.

[0348] Colony formation assay KYSE-520 cells (2000 cells / well) are seeded in 6-well plates containing 2 mL of medium (RPMI-1640 containing 10% FBS) in the presence of DMSO (control; 1% final concentration) or increasing concentrations of compounds. After 14 days of culture at 37°C in a humidified 5% CO2 incubator, colonies are fixed and stained with a solution of 0.1% crystal violet and 15% ethanol. Plates are imaged and colony area is quantified using the Colony Area plugin in ImageJ (Guzman, Camilo, PloSone, 2014) and normalized to the DMSO results. Several compounds of the invention have an IC of less than 1 μM. 50 showed.

[0349] Example 22: In vivo testing The in vivo antitumor efficacy of Example 2b was evaluated in NSG (NOD / scid / gamma) mice implanted subcutaneously with KYSE520 xenografts. Example 2b was administered by oral gavage once daily for 21 days at dose levels of 300 mg / kg, 50 mg / kg, 15 mg / kg, and 5 mg / kg. Example 2b demonstrated dose-dependent tumor growth inhibition in the KYSE520 xenograft model at tolerated doses, as shown in Figure 1.

[0350] The in vivo antitumor efficacy of Example 10b was evaluated in NSG mice implanted subcutaneously with KYSE520 xenografts. Example 10b was administered by oral gavage once daily for 21 days at levels of 200 mg / kg, 150 mg / kg, 100 mg / kg, 30 mg / kg, 10 mg / kg, and 3 mg / kg. Example 10b demonstrated dose-dependent tumor growth inhibition in the KYSE520 xenograft model at tolerated doses, as shown in Figure 2.

[0351] All U.S. or foreign references, patents, or patent applications cited in this application are hereby incorporated by reference as if written in their entirety herein. In the event of any conflict, the text literally disclosed herein will control.

[0352] Those skilled in the art can understand the basic characteristics of the present invention from the above description, and can make various changes and modifications to the present invention in order to adapt the present invention to various applications and conditions without departing from the spirit and scope of the present invention.

[0353] VIII. EMBODIMENTS As further examples, additional non-limiting embodiments of the present invention are provided below.

[0354] Embodiment 1 is a compound of formula I [ka] A compound represented by the formula: the subscript a is 0 or 1; the subscript b is 0 or 1; Y1 is a direct bond or CR 17 R 18 and Y2 is C 1~4 Alkyl, Amino, C 1~4 AlkylC(O)O-, C 1~4 Alkylamino, and C 1~4 aminoalkyl; R1 is C 6~10 Aryl, C 3~8 Cycloalkyl, C 3~8 cycloalkenyl, and 5-10 membered heteroaryl groups having 1-4 heteroatoms or heteroatom groups independently selected from N, C(O), O, and S as ring members, wherein the aryl or heteroaryl of R1 is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkenyl, NR 15 C(O)R 14 , N.R. 15 C(O)OR 14 , N.R. 14 C(O)NR 15 R 16 , N.R. 15 S(O)R 14 , N.R. 15 S(O)2R 14 , C(O)NR 15 R 16 , S(O)NR 15 R 16 , S(O)NR 15 R 16 , C(O)R 14 , C(O)OR 14 , OR 14 , S.R. 14 , S(O)R 14 , and S(O)2R 14 R is independently selected from the group consisting of 1 to 512 is substituted with a group, R2, R3, R 10 , and R 11 is hydrogen, C 1~4 Alkyl, and C 3~8 cycloalkyl; R4, R5, R8, and R9 are hydrogen, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, amino, hydroxy, C 3~8 Cycloalkyl, halo, and C 1~4 alkylamino; R6 is amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino; R7 is selected from the group consisting of hydrogen, amido, cyano, halo, and hydroxy, or R7 is C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 substituted with 1 to 5 groups independently selected from the group consisting of aminoalkyl; or R6 and R7 together with the carbon atom to which they are both attached are N, C(O), O, and S(O). m forming a 3- to 7-membered saturated or unsaturated ring having, as ring members, 0 to 3 heteroatoms or heteroatom groups independently selected from the subscript m is 0, 1, or 2; The saturated or unsaturated ring formed by R6 and R7 is unsubstituted or is selected from the group consisting of amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 substituted with 1 to 3 groups independently selected from the group consisting of aminoalkyl; R2, R3, R4, R5, R7, R8, R9, R 10 , and R 11 any two of the groups may form a 5- or 6-membered ring having 0 to 2 heteroatoms selected from N, O, and S as ring members; R2, R4, R6, R8, and R 10 any two groups may form a direct bond or a one or two carbon bridge; R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, -NH-NHR 19 , -NHR 19 , -OR 19 , -NHC(O)R 19 , -NHC(O)NHR 19 , -NHS(O)2NHR 19 , -NHS(O)2R 19 , -C(O)OR 19 , -C(O)NR 19 R 20 , -C(O)NH(CH2) q OH, -C(O)NH(CH2) q R 21 , -C(O)R 21 , -NH2, -OH, -S(O)2NR 19 R 20 , C 3~8 cycloalkyl, aryl, heterocyclyl having 1 to 5 heteroatoms selected from N, O, S, and P as ring members, and heteroaryl having 1 to 5 heteroatoms selected from N, O, S, and P as ring members, wherein the subscript q is an integer of 0 to 6, and the aryl, heteroaryl, heterocyclyl, and cycloalkyl are selected from C 1~4 Alkyl, -OH, -NH2, -OR 21, halo, cyano, and oxo; R 14 , R 15 , and R 16 is hydrogen, C 1~4 Alkyl, C 3~8 Cycloalkyl, C 6~10 aryl, and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of amido, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 substituted with one or more groups independently selected from the group consisting of: aminoalkyl; R 17 and R 18 is hydrogen, C 1~4 are each independently selected from the group consisting of alkyl, aryl, and CF3; R 19 and R 20 is hydrogen, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, and C 3~6 cycloalkyl; and Each R 21 is hydrogen, -OH, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, and C 3~6 independently selected from the group consisting of cycloalkyl, The compound is a salt, ester, or prodrug thereof.

[0355] Embodiment 2 is a compound of embodiment 1, the subscript a is 0 or 1; the subscript b is 0 or 1; Y1 is a direct bond or CR 17 R 18 and Y2 is C 1~4 Alkyl, Amino, C 1~4 AlkylC(O)O-, C 1~4 Alkylamino, and C 1~4 aminoalkyl; R1 is C 6~10 Aryl, C 3~8 Cycloalkyl, C 3~8 cycloalkenyl, and 5-10 membered heteroaryl groups having 1-4 heteroatoms or heteroatom groups independently selected from N, C(O), O, and S as ring members, wherein the aryl or heteroaryl of R1 is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkenyl, NR 15 C(O)R 14 , N.R. 15 C(O)OR 14 , N.R. 14 C(O)NR 15 R 16 , N.R. 15 S(O)R 14 , N.R. 15 S(O)2R 14 , C(O)NR 15 R 16 , S(O)NR 15 R 16 , S(O)NR 15 R 16 , C(O)R 14 , C(O)OR 14 , OR 14 , S.R. 14 , S(O)R 14 , and S(O)2R14 R is independently selected from the group consisting of 1 to 5 12 is substituted with a group, R2, R3, R 10 , and R 11 is hydrogen, C 1~4 Alkyl, and C 3~8 cycloalkyl; R4, R5, R8, and R9 are hydrogen, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, amino, hydroxy, C 3~8 Cycloalkyl, halo, and C 1~4 alkylamino; R6 is amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino; R7 is selected from the group consisting of hydrogen, halo, and hydroxy, or R7 is amide, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 substituted with 1 to 5 groups independently selected from the group consisting of aminoalkyl; or R6 and R7 together with the carbon atom to which they are both attached are N, C(O), O, and S(O). m forming a 3- to 7-membered saturated or unsaturated ring having, as ring members, 0 to 3 heteroatoms or heteroatom groups independently selected from the subscript m is 0, 1, or 2; The saturated ring formed by R6 and R7 is unsubstituted or is selected from the group consisting of amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 substituted with 1 to 3 groups independently selected from the group consisting of aminoalkyl; R2, R3, R4, R5, R7, R8, R9, R 10 , and R 11 any two of the groups may form a 5- or 6-membered ring having 0 to 2 heteroatoms selected from N, O, and S as ring members; R2, R4, R6, R8, and R 10 any two groups may form a direct bond or a one or two carbon bridge; R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, -NH-NHR 19 , -NHR 19 , -OR 19 , -NHC(O)R 19 , -NHC(O)NHR 19 , -NHS(O)2NHR 19 , -NHS(O)2R 19 , -C(O)OR 19 , -C(O)NR 19 R 20 , -C(O)NH(CH2) q OH, -C(O)NH(CH2) q R 21 , -C(O)R 21 , -NH2, -OH, -S(O)2NR 19 R 20 , C 3~8 cycloalkyl, aryl, heterocyclyl having 1 to 5 heteroatoms selected from N, O, S, and P as ring members, and heteroaryl having 1 to 5 heteroatoms selected from N, O, S, and P as ring members, wherein the subscript q is an integer of 0 to 6, and the aryl, heteroaryl, heterocyclyl, and cycloalkyl are selected from C 1~4Alkyl, -OH, -NH2, -OR 21 , halo, cyano, and oxo; R 14 , R 15 , and R 16 is hydrogen, C 1~4 Alkyl, C 3~8 Cycloalkyl, C 6~10 aryl, and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of halo, hydroxy, cyano, and C 1~4 substituted with one or more groups independently selected from the group consisting of alkyl; R 17 and R 18 is hydrogen, C 1~4 are each independently selected from the group consisting of alkyl, aryl, and CF3; R 19 and R 20 is hydrogen, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, and C 3~6 cycloalkyl; and Each R 21 is hydrogen, -OH, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, and C 3~6 independently selected from the group consisting of cycloalkyl, The compound is as described above.

[0356] Embodiment 3 is a compound of embodiment 1 or 2, wherein the subscripts a and b are each 1.

[0357] Embodiment 4 is a compound of any one of embodiments 1-3, wherein Y1 is a direct bond.

[0358] Embodiment 5 is a compound of any one of embodiments 1 to 4, wherein Y2 is C 1~4 It is an alkyl.

[0359] Embodiment 6 is a compound of embodiment 5, wherein Y2 is methyl.

[0360] Embodiment 7 is a compound of any one of embodiments 1 to 6, R 13 is hydrogen, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, C 3~8 cycloalkyl, 3- or 6-membered heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S as ring members, wherein the heterocyclyl and cycloalkyl are C 1~4 Alkyl, -OH, -NH2, -OR 21 , substituted with 0 to 3 groups independently selected from the group consisting of halo, cyano, and oxo; The compound is as described above.

[0361] Embodiment 8 is the compound of embodiment 7, wherein R 13 is hydrogen, halo, C 1~6 Alkyl, and C 1~6 haloalkyl.

[0362] Embodiment 9 is the compound of embodiment 8, wherein R 13 is hydrogen, Cl, Br, methyl, or CF3.

[0363] Embodiment 10 is a compound of any one of embodiments 1 to 9, R1 is C 6~10 aryl and 5-9 membered heteroaryl groups having 1-4 heteroatoms independently selected from N, C(O), O, and S as ring members, and optionally halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4Alkyl)amino, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkenyl, NR 15 C(O)R 14 , N.R. 15 C(O)OR 14 , N.R. 14 C(O)NR 15 R 16 , N.R. 15 S(O)R 14 , N.R. 15 S(O)2R 14 , C(O)NR 15 R 16 , S(O)NR 15 R 16 , S(O)NR 15 R 16 , C(O)R 14 , C(O)OR 14 , OR 14 , S.R. 14 , S(O)R 14 , and S(O)2R 14 R is independently selected from the group consisting of 1 to 5 12 is substituted with a group, The compound is as described above.

[0364] Embodiment 11 is a compound of embodiment 10, R1 is phenyl or a 5-6 membered heteroaryl group having 1 to 4 heteroatoms independently selected from N, O, and S as ring members, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with a group, The compound is as described above.

[0365] Embodiment 12 is a compound of any one of embodiments 1 to 11, wherein R2, R3, R4, R5, R8, R9, R 10 , and R 11 is hydrogen.

[0366] Embodiment 13 is a compound of any one of embodiments 1 to 12, R6 is amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino; and R7 is selected from the group consisting of hydrogen, amido, cyano, halo, and hydroxy, or R7 is C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 substituted with one or two groups selected from the group consisting of alkoxy; The compound is as described above.

[0367] Embodiment 14 is a compound of embodiment 13, R6 is amino or aminomethyl, and R7 is hydroxy, C 1~4 Alkyl, and C 1~4 hydroxyalkyl, The compound is as described above.

[0368] Embodiment 15 is a compound of any one of embodiments 1 to 12, R6 and R7 together with the carbon atom to which they are both attached form N, C(O), O, and S(O). m and optionally an amino, halo, hydroxy, C1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 forming said saturated or unsaturated ring substituted with one or two groups independently selected from the group consisting of aminoalkyl; The compound is as described above.

[0369] Embodiment 16 is a compound of embodiment 15, R6 and R7 together with the carbon atom to which they are both attached form a 4-6 membered saturated ring having 1-3 heteroatoms independently selected from N and O as ring members, and optionally amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 forming said saturated ring substituted with one or two groups independently selected from the group consisting of aminoalkyl; The compound is as described above.

[0370] Embodiment 17 is a compound of any one of embodiments 1 to 12, R6 and R7, together with the carbon atom to which they are both attached, are optionally amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 forming a 3- to 7-membered cycloalkyl ring substituted with one or two groups independently selected from the group consisting of aminoalkyl; The compound is as described above.

[0371] Embodiment 18 is a compound of any one of embodiments 1 to 17, R1 is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, and 1,2,4-triazinyl, and is optionally selected from halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 has been replaced by The compound is as described above.

[0372] Embodiment 19 is a compound of embodiment 18, wherein R1 is phenyl or pyridyl, each of which has 1 to 3 R 12 has been replaced with.

[0373] Embodiment 20 is a compound of any one of embodiments 1 to 18, wherein R1 is [ka] is selected from the group consisting of Each R 12 Halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 Independently selected from the group consisting of: The compound is as described above.

[0374] Embodiment 21 is a compound of embodiment 20, wherein R1 is [ka] is selected from the group consisting of:

[0375] Embodiment 22 is a compound of any one of embodiments 1 to 21, wherein R 14 C 6~10 aryl and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of halo, hydroxy, cyano, and C 1~4 and substituted with one or more groups independently selected from the group consisting of alkyl.

[0376] Embodiment 23 is a compound of embodiment 22, wherein R 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally selected from halo, hydroxy, cyano, and C 1~4 and substituted with one or two groups independently selected from the group consisting of alkyl.

[0377] Embodiment 24 is a compound of embodiment 1, wherein R 14 C 6~10 aryl and 5-10 membered heteroaryl, each of which is optionally C 1~4 Alkylamide, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 and substituted with one or more groups independently selected from the group consisting of aminoalkyl.

[0378] Embodiment 25 is a compound of embodiment 1, wherein R1 is [ka] and Each R 12 Halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl and C 1~4 aminoalkyl; and R 14 is phenyl or a 5-6 membered heteroaryl having 1-4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4Alkylamide, halo, hydroxy, cyano, and C 1~4 substituted by one or two groups independently selected from the group consisting of alkyl; The compound is as described above.

[0379] Embodiment 26 is a compound of embodiment 1, wherein each R 12 is F, Cl, Br, CH3, OCH3, CF3, [ka] are independently selected from the group consisting of:

[0380] Embodiment 28 is a compound of embodiment 1 or 2 for use as a medicament.

[0381] Embodiment 29 is a compound of embodiment 1 or 2 for use in the treatment of a disease caused by one or more PTPN11 mutations.

[0382] Embodiment 30 is a compound of embodiment 1 or 2 for use in the treatment of cancer.

[0383] Embodiment 31 is a compound of embodiment 30, wherein the cancer is selected from the group consisting of leukemia, melanoma, breast cancer, and colon cancer.

[0384] Embodiment 32 is a compound of embodiment 1 or 2 for use in the manufacture of a medicament for the prevention or treatment of a disease or condition ameliorated by the inhibition of PTPN11.

[0385] Embodiment 33 is a pharmaceutical composition comprising a compound of embodiment 1 or 2 together with a pharma- ceutically acceptable carrier.

[0386] Embodiment 34 is a method of inhibiting PTPN11 comprising contacting PTPN11 with a compound of embodiment 1 or 2.

[0387] Embodiment 35 is a method of treating a PTPN11 mediated disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of embodiment 1 or 2.

[0388] Embodiment 36 is the method of embodiment 35, wherein the disease is cancer.

[0389] Embodiment 37 is the method of embodiment 36, wherein the cancer is selected from the group consisting of breast cancer, colon cancer, leukemia, and melanoma.

[0390] Embodiment 38 is (a) a therapeutically effective amount of a compound of embodiment 1 or 2, and (b) Another medication The present invention relates to a method for treating a PTPN11-mediated disease, the method comprising administering

[0391] Embodiment 39 is the method of embodiment 38, wherein the disease is cancer.

[0392] Embodiment 40 is the method of embodiment 39, wherein the cancer is selected from the group consisting of breast cancer, colon cancer, leukemia, and melanoma.

Claims

1. Formula I: [Formula 1] A compound represented by the formula: the subscript a is 0 or 1; the subscript b is 0 or 1; Y 1 is a direct bond or CR 17 R 18 and Y 2 C 1~4 Alkyl, Amino, C 1~4 Alkyl C(O)O-, C 1~4 Alkylamino, and C 1~4 aminoalkyl; R 1 C 6~10 Aryl, C 3~8 Cycloalkyl, C 3~8 cycloalkenyl, and 5-10 membered heteroaryl groups having 1 to 4 heteroatoms or heteroatom groups independently selected from N, C(O), O, and S as ring members, 1 The aryl or heteroaryl may optionally be halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkenyl, NR 15 C(O)R 14 , N.R. 15 C(O)OR 14 , N.R. 14 C(O)NR 15 R 16 , N.R. 15 S(O)R 14 , N.R. 15 S (O) 2 R 14 , C(O)NR 15 R 16 , S(O)NR 15 R 16 , S(O) 2 N.R. 15 R 16 , C(O)R 14 , C(O)OR 14、 OR 14 , S.R. 14 , S(O)R 14 , and S(O) 2 R 14 R is independently selected from the group consisting of 12 is substituted with a group, R 2 , R 3 , R 10 , and R 11 is hydrogen, C 1~4 Alkyl, and C 3~8 cycloalkyl; R 4 , R 5 , R 8 , and R 9 is hydrogen, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, amino, hydroxy, C 3~8 Cycloalkyl, halo, and C 1~4 alkylamino; R 6 Amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino; R 7 is selected from the group consisting of hydrogen, amido, cyano, halo, and hydroxy, or R 7 C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4Alkylamino, and C 1~4 substituted with 1 to 5 groups independently selected from the group consisting of aminoalkyl; Or R 6 and R 7 together with the carbon atom to which they are both attached: N, C(O), O, and S(O) m forming a 3- to 7-membered saturated or unsaturated ring having, as ring members, 0 to 3 heteroatoms or heteroatom groups independently selected from the subscript m is 0, 1, or 2; R 6 and R 7 wherein the saturated or unsaturated ring formed by 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 substituted with 1 to 3 groups independently selected from the group consisting of aminoalkyl; R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 , and R 11 any two of the groups may form a 5- to 6-membered ring having 0 to 2 heteroatoms selected from N, O, and S as ring members; R 2 , R 4 , R 6 , R 8 , and R 10 any two of the groups may form a direct bond or a one or two carbon bridge; R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, -NH-NHR 19 , -NHR 19 , -OR 19 , -NHC(O)R 19 , -NHC(O)NHR 19 , -NHS(O) 2 NHR 19 , -NHS(O) 2 R 19 , -C(O)OR 19 , -C(O)NR 19 R 20 , -C(O)NH(CH 2 ) q OH, -C(O)NH(CH 2 ) q R 21 , -C(O)R 21 , -NH 2 , -OH, -S(O) 2 N.R. 19 R 20 , C 3~8 cycloalkyl, aryl, heterocyclyl having 1 to 5 heteroatoms selected from N, O, S, and P as ring members, and heteroaryl having 1 to 5 heteroatoms selected from N, O, S, and P as ring members, wherein the subscript q is an integer from 0 to 6, and the aryl, heteroaryl, heterocyclyl, and cycloalkyl are selected from C 1~4 Alkyl, -OH, -NH 2 , -OR 21 , halo, cyano, and oxo; R 14 , R 15 , and R 16 is hydrogen, C 1~4 Alkyl, C 3~8 Cycloalkyl, C 6~10 aryl, and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of amido, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4substituted with one or more groups independently selected from the group consisting of: aminoalkyl; R 17 and R 18 is hydrogen, C 1~4 Alkyl, and CF 3 are each independently selected from the group consisting of: R 19 and R 20 is hydrogen, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, and C 3~6 cycloalkyl; and Each R 21 is hydrogen, -OH, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, and C 3~6 independently selected from the group consisting of cycloalkyl, The compound or a pharma- ceutically acceptable salt thereof.

2. the subscript a is 0 or 1; the subscript b is 0 or 1; Y 1 is a direct bond or CR 17 R 18 and Y 2 C 1~4 Alkyl, Amino, C 1~4 Alkyl C(O)O-, C 1~4 Alkylamino, and C 1~4 aminoalkyl; R 1 C 6~10 Aryl, C 3~8 Cycloalkyl, C 3~8cycloalkenyl, and 5-10 membered heteroaryl groups having 1 to 4 heteroatoms or heteroatom groups independently selected from N, C(O), O, and S as ring members, 1 The aryl or heteroaryl may optionally be halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkenyl, NR 15 C(O)R 14 , N.R. 15 C(O)OR 14 , N.R. 14 C(O)NR 15 R 16 , N.R. 15 S(O)R 14 , N.R. 15 S (O) 2 R 14 , C(O)NR 15 R 16 , S(O)NR 15 R 16 , S(O) 2 N.R. 15 R 16 , C(O)R 14 , C(O)OR 14 , OR 14 , S.R. 14 , S(O)R 14 , and S(O) 2 R 14 R is independently selected from the group consisting of 12 is substituted with a group, R 2 , R 3 , R 10 , and R 11 is hydrogen, C 1~4 Alkyl, and C 3~8 cycloalkyl; R 4 , R 5 , R 8 , and R 9 is hydrogen, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, amino, hydroxy, C 3~8 Cycloalkyl, halo, and C 1~4 alkylamino; R 6 Amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino; R 7 is selected from the group consisting of hydrogen, halo, and hydroxy, or R 7 is amide, C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~4 substituted with 1 to 5 groups independently selected from the group consisting of aminoalkyl; Or R 6 and R 7 together with the carbon atom to which they are both attached: N, C(O), O, and S(O) m forming a 3- to 7-membered saturated or unsaturated ring having, as ring members, 0 to 3 heteroatoms or heteroatom groups independently selected from the subscript m is 0, 1, or 2; R 6 and R 7 wherein the saturated ring formed by 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4Alkylamino, and C 1~4 substituted with 1 to 3 groups independently selected from the group consisting of aminoalkyl; R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , R 9 , R 10 , and R 11 any two of the groups may form a 5- to 6-membered ring having 0 to 2 heteroatoms selected from N, O, and S as ring members; R 2 , R 4 , R 6 , R 8 , and R 10 any two of the groups may form a direct bond or a one or two carbon bridge; R 13 is hydrogen, halo, cyano, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, -NH-NHR 19 , -NHR 19 , -OR 19 , -NHC(O)R 19 , -NHC(O)NHR 19 , -NHS(O) 2 NHR 19 , -NHS(O) 2 R 19 , -C(O)OR 19 , -C(O)NR 19 R 20 , -C(O)NH(CH 2 ) q OH, -C(O)NH(CH 2 ) q R 21 , -C(O)R 21 , -NH 2 , -OH, -S(O) 2 N.R. 19 R 20 , C 3~8cycloalkyl, aryl, heterocyclyl having 1 to 5 heteroatoms selected from N, O, S, and P as ring members, and heteroaryl having 1 to 5 heteroatoms selected from N, O, S, and P as ring members, wherein the subscript q is an integer from 0 to 6, and the aryl, heteroaryl, heterocyclyl, and cycloalkyl are selected from C 1~4 Alkyl, -OH, -NH 2 , -OR 21 , halo, cyano, and oxo; R 14 , R 15 , and R 16 is hydrogen, C 1~4 Alkyl, C 3~8 Cycloalkyl, C 6~10 aryl, and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of halo, hydroxy, cyano, and C 1~4 substituted with one or more groups independently selected from the group consisting of alkyl; R 17 and R 18 is hydrogen, C 1~4 Alkyl, and CF 3 are each independently selected from the group consisting of: R 19 and R 20 is hydrogen, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, and C 3~6 cycloalkyl; and Each R 21 is hydrogen, -OH, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 2~6 Alkenyl, C 2~6 Alkynyl, and C 3~6 independently selected from the group consisting of cycloalkyl, 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.

3. 3. The compound of claim 1 or 2, wherein the subscripts a and b are each 1, or a pharma- ceutically acceptable salt thereof.

4. Y 1 The compound according to any one of claims 1 to 3, or a pharma- ceutically acceptable salt thereof, wherein is a direct bond.

5. Y 2 C 1~4 The compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein R is an alkyl group.

6. Y 2 6. The compound of claim 5, or a pharma- ceutically acceptable salt thereof, wherein is methyl.

7. R 13 is hydrogen, halo, C 1~6 Alkyl, C 1~6 Haloalkyl, C 1~6 Hydroxyalkyl, C 1~6 Dihydroxyalkyl, C 3~8 cycloalkyl, 3- or 6-membered heterocyclyl having 1 to 3 heteroatoms selected from N, O, and S as ring members, wherein the heterocyclyl and cycloalkyl are C 1~4 Alkyl, -OH, -NH 2 , -OR 21 , substituted with 0 to 3 groups independently selected from the group consisting of halo, cyano, and oxo; 7. The compound according to any one of claims 1 to 6, or a pharma- ceutically acceptable salt thereof.

8. R 13 is hydrogen, halo, C 1~6 Alkyl, and C 1~6 8. The compound of claim 7, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of haloalkyl.

9. R 13 is hydrogen, Cl, Br, methyl, or CF 39. The compound of claim 8, which is: or a pharma- ceutically acceptable salt thereof.

10. R 1 C 6~10 aryl and 5-9 membered heteroaryl groups having 1-4 heteroatoms as ring members independently selected from N, C(O), O, and S, and optionally halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Hydroxyalkyl, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, C 3~8 Cycloalkyl, C 3~8 Cycloalkenyl, NR 15 C(O)R 14 , N.R. 15 C(O)OR 14 , N.R. 14 C(O)NR 15 R 16 , N.R. 15 S(O)R 14 , N.R. 15 S (O) 2 R 14 , C(O)NR 15 R 16 , S(O)NR 15 R 16 , S(O) 2 N.R. 15 R 16 , C(O)R 14 , C(O)OR 14 , OR 14 , S.R. 14 , S(O)R 14 , and S(O) 2 R 14 R is independently selected from the group consisting of 12 is substituted with a group, 10. The compound according to any one of claims 1 to 9, or a pharma- ceutically acceptable salt thereof.

11. R 1is phenyl or a 5-6 membered heteroaryl group having 1 to 4 heteroatoms independently selected from N, O, and S as ring members, and optionally halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 is substituted with a group, 11. The compound of claim 10, or a pharma- ceutically acceptable salt thereof.

12. R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , R 10 , and R 11 The compound according to any one of claims 1 to 11, or a pharma- ceutically acceptable salt thereof, wherein is hydrogen.

13. R 6 Amino, C 1~4 Aminoalkyl, and C 1~4 alkylamino; and R 7 is selected from the group consisting of hydrogen, amido, cyano, halo, and hydroxy, or R 7 C 1~4 Alkyl, C 1~4 Hydroxyalkyl, C 3~6 cycloalkyl, phenyl, and 5- or 6-membered heteroaryl, any of which is optionally selected from the group consisting of amino, halo, hydroxy, cyano, trifluoromethyl, trifluoromethoxy, C 1~4 Alkyl, and C 1~4 substituted with one or two groups selected from the group consisting of alkoxy; 13. The compound according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt thereof.

14. R 6 is amino or aminomethyl, and R 7 is hydroxy, C 1~4 Alkyl, and C 1~4 hydroxyalkyl, 14. The compound of claim 13, or a pharma- ceutically acceptable salt thereof.

15. R 6 and R 7 together with the carbon atom to which they are both attached: N, C(O), O, and S(O) m and optionally containing amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 forming said saturated or unsaturated ring substituted with one or two groups independently selected from the group consisting of aminoalkyl; 13. The compound according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt thereof.

16. R 6 and R 7 are both attached to the carbon atom to form a 4-6 membered saturated ring having 1 to 3 heteroatoms independently selected from N and O as ring members, and optionally amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 forming said saturated ring substituted with one or two groups independently selected from the group consisting of aminoalkyl; 16. The compound of claim 15, or a pharma- ceutically acceptable salt thereof.

17. R 6 and R 7together with the carbon atom to which they are both attached, optionally amino, halo, hydroxy, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Alkylamino, and C 1~4 forming a 3- to 7-membered cycloalkyl ring substituted with 1 or 2 groups independently selected from the group consisting of aminoalkyl; 13. The compound according to any one of claims 1 to 12, or a pharma- ceutically acceptable salt thereof.

18. R 1 is selected from the group consisting of phenyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, and 1,2,4-triazinyl, and optionally halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Aminoalkyl, and OR 14 one, two, or three R independently selected from the group consisting of 12 has been replaced by 18. The compound according to any one of claims 1 to 17, or a pharma- ceutically acceptable salt thereof.

19. R 1 is phenyl or pyridyl, each of which is 1 to 3 R 12 20. The compound of claim 18, or a pharma- ceutically acceptable salt thereof, substituted with:

20. R 1 but [Case 2] is selected from the group consisting of Each R 12 Halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4Aminoalkyl, and OR 14 Independently selected from the group consisting of:

19. The compound according to any one of claims 1 to 18, or a pharma- ceutically acceptable salt thereof.

21. R 1 but [C3] 21. The compound of claim 20, selected from the group consisting of: or a pharma- ceutically acceptable salt thereof.

22. R 14 C 6~10 aryl and 5-10 membered heteroaryl, each of which is optionally selected from the group consisting of halo, hydroxy, cyano, and C 1~4 22. The compound of any one of claims 1 to 21, or a pharma- ceutically acceptable salt thereof, substituted by one or more groups independently selected from the group consisting of alkyl.

23. R 14 is phenyl or a 5-6 membered heteroaryl having 1 to 4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally selected from halo, hydroxy, cyano, and C 1~4 23. The compound of claim 22, or a pharma- ceutically acceptable salt thereof, substituted with one or two groups independently selected from the group consisting of alkyl.

24. R 14 C 6~10 aryl and 5-10 membered heteroaryl, each of which is optionally C 1~4 Alkylamide, amino, halo, hydroxy, cyano, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, C 1~4 Haloalkoxy, C 1~4 Alkylamino, and C 1~42. The compound of claim 1, or a pharma- ceutically acceptable salt thereof, substituted with one or more groups independently selected from the group consisting of aminoalkyl.

25. R 1 but [C4] and Each R 12 Halo, hydroxy, amino, C 1~4 Alkylamino, di(C 1~4 Alkyl)amino, C 1~4 Alkyl, C 1~4 Alkoxy, C 1~4 Haloalkyl, and C 1~4 aminoalkyl; and R 14 is phenyl or a 5-6 membered heteroaryl having 1 to 4 heteroatoms as ring members independently selected from N, O, and S, each of which is optionally C 1~4 Alkylamide, halo, hydroxy, cyano, and C 1~4 substituted by one or two groups independently selected from the group consisting of alkyl; 2. The compound of claim 1, or a pharma- ceutically acceptable salt thereof.

26. Each R 12 is F, Cl, Br, CH 3 , O.C.H. 3 , C.F. 3 , [C5] 2. The compound of claim 1, independently selected from the group consisting of:

27. ​​

6. [C7] [C8] [C9] 2. The compound of claim 1 having a structure selected from the group consisting of:

28. The formula: [C10] or a pharma- ceutically acceptable salt thereof.

29. The formula: [C11] The compound represented by:

30. The following formula: [C12] A pharmacy acceptable salt of a compound represented by:

31. The following formula: [C13] The compound represented by:

32. The formula: [C14] A pharmacy acceptable salt of a compound represented by:

33. The formula: [C15] or a pharma- ceutically acceptable salt thereof.

34. An in vitro method for inhibiting PTPN11, comprising contacting PTPN11 with a compound described in any one of claims 1 to 33 or a pharma- ceutically acceptable salt thereof.

35. A pharmaceutical composition for treating a PTPN11-mediated disease, comprising a therapeutically effective amount of a compound according to any one of claims 1 to 33 or a pharma- ceutically acceptable salt thereof.

36. The pharmaceutical composition described in claim 35, wherein the PTPN11-mediated disease is Noonan syndrome, LEOPARD syndrome, or cancer.

37. The pharmaceutical composition of claim 36, wherein the cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, esophageal cancer, gastric cancer, leukemia and melanoma.

38. A pharmaceutical composition for treating a PTPN11 mediated disease, comprising: a. a therapeutically effective amount of a compound according to any one of claims 1 to 33, or a pharma- ceutically acceptable salt thereof; and b. Another therapeutic agent wherein said composition is administered to a patient in need of treatment.

39. The pharmaceutical composition described in claim 38, wherein the PTPN11-mediated disease is Noonan syndrome, LEOPARD syndrome, or cancer.

40. The pharmaceutical composition of claim 39, wherein the cancer is selected from the group consisting of breast cancer, colon cancer, lung cancer, esophageal cancer, gastric cancer, leukemia, and melanoma.

41. The compound of claim 41, wherein the compound has the following formula: [C16] 40. The pharmaceutical composition of claim 35 or 38, which is a compound represented by: or a pharma- ceutically acceptable salt thereof.

42. The compound of claim 42, wherein the compound has the following formula: [C17] 40. The pharmaceutical composition of claim 35 or 38, which is a compound represented by:

43. The compound of claim 43, wherein the compound has the following formula: [C18] 39. The pharmaceutical composition of claim 35 or 38, wherein the pharmaceutical composition is represented by:

44. The compound of claim 43, wherein the compound has the following formula: [C19] 40. The pharmaceutical composition of claim 35 or 38, which is a compound represented by:

45. The compound of claim 45, wherein the compound has the following formula: [C20] 39. The pharmaceutical composition of claim 35 or 38, wherein the pharmaceutical composition is represented by:

46. ​​The compound of claim 4, wherein the compound has the following formula: [C21] 40. The pharmaceutical composition of claim 35 or 38, which is a compound represented by:

Citation Information

Patent Citations

  • Compounds and compositions for inhibiting SHP2 activity

    JP2018517746A

  • Heterocyclic compound and application thereof

    WO2012011592A1

  • Novel heterocyclic derivatives useful as SHP2 inhibitors

    WO2017211303A1

  • Pyridine compounds as allosteric SHP2 inhibitors

    WO2018136264A1